Catheter Precision (VTAK) 10-K 17 Mar 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Mar. 10, 2021	Jun. 30, 2020
Cover [Abstract]
Entity Registrant Name	Ra Medical Systems, Inc.
Entity Central Index Key	0001716621
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Trading Symbol	RMED
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		3,259,340
Entity Public Float			$ 18.5
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Shell Company	false
Entity Ex transition period	false
Title of 12(b) Security	Common Stock, $0.0001 par value
Security Exchange Name	NYSEAMER
Entity Tax Identification Number	38-3661826
Entity Address, Address Line One	2070 Las Palmas Drive
Entity File Number	001-38677
Entity Address, City or Town	Carlsbad
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92011
City Area Code	760
Local Phone Number	804-1648
Document Transition Report	false
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes
Document Annual Report	true

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents	$ 23,906	$ 14,584
Short-term investments		15,993
Accounts receivable, net	238	786
Inventories	2,218	2,777
Prepaid expenses and other current assets	1,258	1,860
Total current assets	27,620	36,000
Property and equipment, net	3,211	5,050
Operating lease right-of-use-assets	2,484	2,835
Other non-current assets	123	196
TOTAL ASSETS	33,438	44,081
Current Liabilities
Accounts payable	571	1,532
Accrued expenses	4,348	2,642
Current portion of deferred revenue	1,801	2,029
Current portion of equipment financing	265	293
Current portion of promissory note	421
Current portion of operating lease liabilities	356	318
Total current liabilities	7,762	6,814
Deferred revenue	686	1,232
Promissory note	1,579
Operating lease liabilities	2,264	2,620
Equipment financing		265
Total liabilities	12,291	10,931
Commitments and contingencies (Note 15)
Stockholders’ Equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized at December 31, 2020 and 2019; none issued
Common stock, $0.0001 par value, 300,000,000 shares authorized at December 31, 2020 and 2019; 3,188,679 and 550,814 issued and outstanding at December 31, 2020 and 2019, respectively	7	1
Additional paid-in capital	174,342	150,280
Accumulated deficit	(153,202)	(117,157)
Accumulated other comprehensive income		26
Total stockholders’ equity	21,147	33,150
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 33,438	$ 44,081

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	3,188,679	550,814
Common stock, shares outstanding	3,188,679	550,814

Statements of Operations

Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Net revenue
Total net revenue	$ 4,405	$ 7,199
Cost of revenue
Total cost of revenue	5,482	8,850
Gross loss	(1,077)	(1,651)
Operating expenses
Selling, general and administrative	25,974	51,549
Research and development	9,008	4,530
Total operating expenses	34,982	56,079
Operating loss	(36,059)	(57,730)
Other income (expense), net
Interest income	129	1,038
Interest expense	(108)	(250)
Total other income (expense), net	21	788
Loss before income tax expense	(36,038)	(56,942)
Income tax expense	7	15
Net loss	$ (36,045)	$ (56,957)
Basic and diluted net loss per share	$ (21.22)	$ (108.28)
Basic and diluted weighted average common shares outstanding	1,699	526
Product Sales [Member]
Net revenue
Total net revenue	$ 1,407	$ 3,859
Cost of revenue
Total cost of revenue	2,890	5,856
Service and Other [Member]
Net revenue
Total net revenue	2,998	3,340
Cost of revenue
Total cost of revenue	$ 2,592	$ 2,994

Statements of Comprehensive Los

Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (36,045)	$ (56,957)
Other comprehensive income:
Unrealized (loss) gain related to short-term investments	(26)	26
Total other comprehensive income	(26)	26
Comprehensive loss	$ (36,071)	$ (56,931)

Statements of Stockholders' Equ

Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid- in- Capital	Accumulated Other Comprehensive Income	Accumulated Deficit
Balances at Dec. 31, 2018	$ 66,726	$ 1	$ 126,925		$ (60,200)
Balance (in shares) at Dec. 31, 2018		508
Common stock issued	(188)		(188)
Common stock issued (in shares)		43
Stock-based compensation	23,543		23,543
Other comprehensive income (loss)	26			$ 26
Net loss	(56,957)				(56,957)
Balances at Dec. 31, 2019	33,150	$ 1	150,280	26	(117,157)
Balance (in shares) at Dec. 31, 2019		551
Common stock issued	11,625	$ 5	11,620
Common stock issued (in shares)		2,551
Warrants issued, net	7,492		7,492
Exercise of warrants	827	$ 1	826
Exercise of warrants (in shares)		74
Common stock issued pursuant to the vesting of restricted stock units and ESPP	42		42
Common stock issued pursuant to the vesting of restricted stock units and ESPP (in shares)		13
Stock-based compensation	4,082		4,082
Other comprehensive income (loss)	(26)			$ (26)
Net loss	(36,045)				(36,045)
Balances at Dec. 31, 2020	$ 21,147	$ 7	$ 174,342		$ (153,202)
Balance (in shares) at Dec. 31, 2020		3,189

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (36,045)	$ (56,957)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,365	1,750
Provision for doubtful accounts	180	283
Stock-based compensation	4,082	23,543
Loss on disposal of property and equipment	99	123
Changes in operating assets and liabilities:
Accounts receivable	368	251
Inventories	352	(2,185)
Prepaid expenses and other assets	642	(338)
Accounts payable	(961)	407
Accrued expenses	1,706	(184)
Deferred revenue	(774)	417
Other liabilities	(318)	(283)
Net cash used in operating activities	(28,304)	(33,173)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of available-for-sale securities		(36,461)
Proceeds from maturities of available-for-sale securities	16,000	20,697
Purchases of property and equipment	(67)	(268)
Net cash provided by (used in) investing activities	15,933	(16,032)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants, net of placement agent fees of $2,113	19,887
Proceeds from issuance of common stock in connection with the exercise of warrants	827
Proceeds from issuance of common stock in connection with the employee stock purchase plan	42	37
Proceeds from promissory note	2,000
Payments of offering costs related to the issuance of common stock and warrants	(770)
Payments on equipment financing	(293)	(338)
Payments for restricted stock tax liability on settlement		(225)
Net cash provided by (used in) financing activities	21,693	(526)
NET CHANGE IN CASH AND CASH EQUIVALENTS	9,322	(49,731)
CASH AND CASH EQUIVALENTS, beginning of year	14,584	64,315
CASH AND CASH EQUIVALENTS, end of year	23,906	14,584
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Transfer from inventories to property and equipment for lasers	207	1,505
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash payments for interest	$ 28	49
Cash payments for taxes		$ 30

Statements of Cash Flows (Paren

Statements of Cash Flows (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Statement Of Cash Flows [Abstract]
Underwriters' discount	$ 2,113

Organization and Nature of Oper

Organization and Nature of Operations	12 Months Ended
	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Nature of Operations	Note 1—Organization and Nature of Operations Ra Medical Systems, Inc. (the “Company”) was formed in September 4, 2002, in the state of California and reincorporated in Delaware on July 14, 2018. The Company is a medical device company that develops, manufactures and markets advanced excimer laser systems for use in the treatment of vascular and dermatological diseases. The Company’s product development centers around proprietary applications of its advanced excimer laser technology for use as a tool in the treatment of peripheral artery disease (“PAD”) and psoriasis, vitiligo, atopic dermatitis and leukoderma. Reincorporation —In July 2018, the Company reincorporated in Delaware, the par value of each share of common stock was established to be $0.0001 and the number of authorized shares of common stock was increased from 10,000,000 to 25,000,000. In connection with the reincorporation, common stock and additional paid-in capital amounts in these financial statements have been adjusted to reflect the par value of common stock. All share information included in these financial statements has been adjusted to reflect this reincorporation. Initial Public Offering— On October 1, 2018, the Company closed its initial public offering ("IPO"). The Company’s registration statement on Form S-1 relating to its IPO was declared effective by the Securities and Exchange Commission on September 26, 2018. In October 2018, in connection with the IPO, the Company filed an Amended and Restated Certificate of Incorporation which authorizes the issuance of 300,000,000 shares of common stock with a par value of $0.0001 and 10,000,000 shares of preferred stock with a par value of $0.0001. Reverse Stock Split — In November 2020, the board of directors approved a Reverse Stock Split ratio of 1-for-25 On the effective date of November 16, 2020, the number of the Company’s issued and outstanding shares of common stock was decreased from 73.0 million shares to 2.9 million shares. The number of authorized shares and par value per common share remained unchanged. No fractional shares were issued as a result of the reverse stock split. Stockholders who would otherwise have been entitled to receive a fractional share received a cash payment in lieu thereof. The financial statements have been retrospectively adjusted to reflect the 1-for-25 reverse stock split of our common stock COVID-19 — The global spread of the novel coronavirus (COVID-19) has created significant volatility, uncertainty and economic disruption. The ultimate effects of the COVID-19 on the Company’s business, operations and financial condition are unknown at this time. In the near term, the Company expects that its revenue will continue to be adversely impacted and enrollment in its atherectomy clinical trial will continue to be delayed or slowed, as patients elect to postpone voluntary treatments and many physicians’ offices have been either closed or operating at a reduced capacity. In addition, some customers are requesting more flexible payment terms on a temporary basis. The Company’s manufacturing facility located in Carlsbad, California is currently operational. Employee travel is limited to essential travel only and many employees are working from home when feasible. The Company has experienced minor delays in receiving shipments of parts, which has not had a material impact on the timing of its key engineering efforts, nor ability to support its atherectomy indication clinical trial. However, the extent to which COVID-19 impacts its business will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain it or treat its impact, among others. Going Concern —The Company has experienced recurring net losses from operations and negative cash flows from operating activities, has a significant accumulated deficit and expects to continue to incur net losses into the foreseeable future. The Company had an accumulated deficit of $153.2 million at December 31, 2020. In 2020, the Company used $28.3 million in cash for operating activities. As of December 31, 2020 the Company had cash and cash equivalents of $23.9 million. Management expects operating losses and negative cash flows to continue for the foreseeable future with the Company’s reduced commercial footprint, and as the Company continues to incur costs related to its atherectomy clinical trial, engineering efforts to improve the shelf-life of its catheters and develop next generation products and legal costs associated with ongoing litigation. In September 2020, the Company paused commercial sales of DABRA catheters not being used for the atherectomy clinical trial while it conducts further studies on the stability of its shelf life. We submitted additional test data in March 2021, which will need to be cleared by the FDA prior to resuming commercial shipments of catheters. The Company also expects the COVID-19 pandemic to have a continued negative impact on its revenue and the timing of enrollment in its atherectomy clinical trial as well as the Company’s ability to secure additional financing in a timely manner or on favorable terms, if at all. Although the Company bolstered its liquidity resources in 2020, has an effective shelf registration statement and an “at the market” offering to allow it to raise additional capital when the opportunities permit and may receive additional funds from the exercise of its warrants depending on market conditions, management concluded that the aforementioned conditions, including the ongoing uncertainty related to the negative impacts of the COVID-19 pandemic, continue to raise substantial doubt about the Company’s ability to continue as a going concern within 12 months from the date of issuance of the financial statements. Management’s plans to address this uncertainty include raising additional funding, if necessary, through public or private equity or debt financings. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. The financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Significant Accounting Policies	Note 2—Significant Accounting Policies Use of estimates —The financial statements of the Company have been prepared by management in accordance with accounting principles generally accepted in the United States of America. The preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and reported disclosures of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. The Company’s financial statements are based upon a number of estimates, including but not limited to, allowance for doubtful accounts, reserves for warranty costs including product recalls, evaluation of probable loss contingencies, fair value of stock option awards granted and revenue recognition for multiple performance obligations. Short-term Investments — I nvestments with original maturities of greater than three months are classified as short-term investments. Debt investments are classified as available-for-sale and realized gains and losses are recorded using the specific identification method. Changes in fair value, excluding other-than-temporary impairments, are recorded in other comprehensive income (“OCI”). Debt investments are impaired when a decline in fair value is judged to be other-than-temporary. Fair value is calculated based on publicly available market information or other estimates determined by management. The Company employs a systematic methodology on a quarterly basis that considers available quantitative and qualitative evidence in evaluating potential impairment of our investments. If the cost of an investment exceeds its fair value, the Company evaluates, among other factors, general market conditions, credit quality of debt instrument issuers, and the duration and extent to which the fair value is less than cost. The Company also evaluates whether it has plans to sell the security or it is more likely than not that the Company will be required to sell the security before recovery. In addition, the Company considers specific adverse conditions related to the financial health of and business outlook for the investee, including industry and sector performance, changes in technology, and operational and financing cash flow factors. Once a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in other income (expense), net and a new cost basis in the investment is established. Fair value measurements — Fair value represents the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants and is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier value hierarchy is used to identify inputs used in measuring fair value as follows: Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets. Level 2—Inputs other than the quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. The hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company measures its cash and cash equivalents and short-term investments at fair value. Fair value of financial instruments —Cash and cash equivalents, trade accounts receivable, accounts payable, accrued expenses, deferred revenue and other current assets and liabilities are reported on the balance sheets at carrying value which approximates fair value due to the short-term maturities of these instruments. The fair value of the Company’s debt, which is classified as equipment financing liability on the balance sheets, is estimated based on current rates offered to the Company for similar debt and approximates carrying value. Cash and cash equivalents —The Company considers all short-term, highly liquid investments with original maturities of three months or less to be cash equivalents. Cash equivalents primarily represent funds invested in readily available checking and money market accounts. The Company maintains deposits in financial institutions in excess of federally insured limits. Accounts receivable, net —Trade accounts receivable are presented net of allowances for doubtful accounts. The Company sells or leases its lasers to distributors or physicians directly with various forms of financing options. The Company extends credit based on an evaluation of the customers’ financial condition generally without requiring collateral. Exposure to losses on trade receivables is expected to vary by customer due to the financial condition of each customer. The Company monitors exposure to credit losses and maintains allowances for anticipated losses considered necessary under the circumstances. The Company maintains an allowance for doubtful accounts for balances that appear to have specific collection issues and expected credit losses. The collection process is based on the age of the invoice and requires attempted contacts with the customer at specified intervals. If, after a specified number of days, the Company has been unsuccessful in its collection efforts, provision for doubtful accounts is recorded for the balance in question. Delinquent accounts receivable are charged against the allowance for doubtful accounts once the Company has determined the amounts are uncollectible. The factors considered in reaching this determination are the apparent financial condition of the customer and the Company’s success in contacting and negotiating with the customer. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. The following table shows the allowance for doubtful accounts activity (in thousands): Year Ended December 31, 2020 2019 Balance at beginning of period $ 355 $ 214 Provision for doubtful accounts 180 283 Deductions (264 ) (142 ) Balance at end of period $ 271 $ 355 Inventories —Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. Cost includes materials, labor and manufacturing overhead related to the purchase and production of inventories. The Company reduces the carrying value of inventories for those items that are potentially excess, obsolete or slow-moving based on changes in customer demand, technological developments or other economic factors. Catheters are manufactured in-house and each catheter is tested at various stages of the manufacturing process for adherence to quality standards. Catheters that do not meet functionality specification at each test point are destroyed and immediately written off, with the expense recorded in cost of revenue in the statements of operations. Once manufactured, completed catheters that pass quality assurance, are sent to a third-party for sterilization and sealed in a sterile container. Upon return from the third-party sterilizer, a sample of catheters from each batch are re-tested. If the sample tests are successful, the batch is accepted into finished goods inventory and if the sample tests are unsuccessful, the entire batch is written off, with the expense recorded in cost of revenue in the statements of operations. Property and equipment, net —Property and equipment are recorded at cost and are depreciated on a straight-line basis over their estimated useful lives as follows: Computer hardware and software 4-5 years Furniture and fixtures 5 years Machinery and equipment 5-10 years Lasers 3-5 years Automobiles 5 years Leasehold improvements are depreciated over the shorter of the useful life of the leasehold improvement or the term of the underlying property’s lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the account balances and any resulting gain or loss is recognized in income for the period. The cost of repairs and maintenance is expensed as incurred, whereas significant betterments are capitalized. Impairment of long-lived assets —The Company periodically reviews its long-lived assets for impairment when certain events or changes in circumstances indicate that the carrying value of the long-lived assets may not be recoverable. Should the sum of the undiscounted expected future net cash flows be less than the carrying value, the Company would recognize an impairment loss at that date. The inconsistencies in the DABRA catheter performance, the voluntary product recall and the reduction in the sales force resulted in lower current and expected revenues for the vascular segment, led the Company to accelerate its annual testing for asset impairment into the third quarter of 2019. There were no impairment charges for the years ended December 31, 2020 or 2019. Product warranty —The Company records estimated product warranty costs at the time of sale. Products are warrantied against defects in material and workmanship when properly used for their intended purpose and appropriately maintained. Accordingly, the Company generally replaces catheters that kink or fail to calibrate. The product warranty liability is determined based on historical information such as past experience, product failure rates or number of units repaired, estimated cost of material and labor. The product warranty liability also includes the estimated costs of a product recall. Product warranties are included for the first year after the sale for laser sales. For lasers, the customer may purchase an extended service contract, which is either negotiated in the contract or sold as a separate component for which revenue is recognized over the term of the agreement. The warranty accrual is included in accrued expenses in the accompanying balance sheets. Warranty expenses are included in cost of revenue in the accompanying statements of operations. Changes in estimates to previously established warranty accruals result from current period updates to assumptions regarding repair and product recall costs and are included in current period warranty expense. Revenue recognition —The Company adopted ASC Topic 606 (Topic 606), Revenue from Contracts with Customers , on January 1, 2019 using the modified retrospective method to all contract agreements not completed as of January 1, 2019. Results for reporting periods beginning after January 1, 2019 are presented under Topic 606 while, as permitted by Topic 606, prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. The Company recorded a cumulative catch up adjustment to beginning accumulated deficit to reflect the impact of adopting Topic 606. The adoption of Topic 606 did not have a material effect on our results of operations for the year ended December 31, 2019. The Company generates revenue from the sale of products and services. Product sales consist of the sale of DABRA and Pharos laser systems, the sale of catheters for use with the DABRA laser, and the sale of consumables and replacement parts. The Company’s sales agreements generally do not include right-of-return provisions for any form of consideration including partial refund or credit against amounts owed to the Company. Services and other revenue primarily consist of sales of extended warranty and billable services, including repair activity and income from rental of lasers. The Company determines revenue recognition incorporating the following steps: • Identification of each contract with a customer; • Identification of the performance obligations in the contract; • Determination of the transaction price; • Allocation of the transaction price to the performance obligations in the contract; and • Recognition of revenue when, or as, performance obligations are satisfied. The Company accounts for a contract with a customer when it has a legally enforceable contract with the customer, the arrangement identifies the rights of the parties, the contract has commercial substance, and the Company determines it is probable that it will collect the contract consideration. The Company recognizes revenue when control of the promised goods or services transfers to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Taxes collected from customers relating to goods or services and remitted to governmental authorities are excluded from revenue. Catheter Revenue The Company enters into a DABRA laser commercial usage agreement or DABRA laser placement acknowledgement with each customer that is supplied a DABRA laser, collectively the “usage agreement”. The usage agreement provides for specific terms of continued use of DABRA laser, including a nominal periodic fee. The terms of a usage agreement typically allow the Company to place a DABRA laser at a customer’s specified location without a specified contract term. Under the usage agreement terms, the Company retains all ownership rights to the DABRA laser and is permitted to request the return of the equipment within 10 business days of notification. While the laser periodic fees are nominal, the laser usage agreements provide the Company the exclusive rights to supply related single-use catheters to the customer which aggregate the majority of the vascular segment revenue. There are no specified minimum purchase commitments for the catheters. The Company recognizes revenue associated with the usage agreement and catheter supply arrangements in accordance with Topic 606 as the contract primarily includes variable payments, the catheters are priced at their standalone selling price and the laser equipment is insignificant in the context of the contract. Revenue is recognized when the performance obligation is satisfied, which is generally upon shipment of the catheter. Laser Sales Sales of laser systems and are included in product sales in the statements of operations. The Company recognizes revenue on laser sales at the point in time that control transfers to the customer. Control of the product typically transfers upon shipment. Warranty Service Revenue The Company typically provides a 12-month warranty with the purchase of its laser systems. Customers can extend the warranty period through the purchase of extended warranty service contracts. Extended warranty service contracts are sold with contract terms ranging from 12 to 60 months and cover periods after the end of the initial 12-month warranty period. The warranty provides the customer with maintenance services in addition to the assurance that the laser product complies with agreed-upon specifications. Therefore, the warranty service is treated as a separate performance obligation from the laser system. Warranty services are a stand-ready obligation, and the Company recognizes revenue on a straight-line basis over the service contract term. Warranty service revenue is included in service and other revenue in the statements of operations. Deferred revenue, on January 1, 2020 and 2019, was $3.3 million and $2.8 million, respectively. Revenue recognized in the years ended December 31, 2020 and 2019 relating to amounts previously included in deferred revenue was $2.0 million and $1.9 million, respectively. The deferred revenue greater than one year will be recognized during the remaining service period through 2024. Distributor Transactions In certain markets outside the U.S., the Company sells products and provides services to customers through distributors that specialize in medical device products. The terms of sales transactions through distributors are generally consistent with the terms of direct sales to customers. The Company accounts for these transactions in accordance with the Company’s revenue recognition policy described herein. Contracts with multiple performance obligations Certain of the Company’s contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if (i) a product or service is separately identifiable from other items in the arrangement and (ii) the customer can benefit from the product or service on its own or with other readily available resources. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling prices based on observable prices of products or services sold separately in comparable circumstances to similar customers. Significant Financing Component For multi-year warranty service contracts in which there is a difference between the cash selling price and the consideration in the contract and a significant amount of time between the payment, which is due up-front, and delivery of the services (greater than one year), the Company records an adjustment for significant financing to reflect the time value of money. The Company recognizes revenue associated with the cash selling price and interest expense using the effective interest method as the Company satisfies its performance obligation(s). The amount of interest expense the Company recognizes over the contract term is based on the contract liability balance, which increases for the accrual of interest and decreases as services are provided. For services contracts that have an original duration of one year or less, the Company uses the practical expedient applicable to such contracts and does not adjust the transaction price for the time value of money. Practical expedients elected As part of the Company’s adoption of Topic 606, the Company elected to use the following practical expedients: • not to adjust the promised amount of consideration for the effects of a significant financing component when the Company expects, at contract inception, that the period between the Company’s transfer of a promised product or service to a customer and when the customer pays for that product or service will be one year or less; • to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less; • to exclude government assessed taxes from the transaction price; and • not to recast revenue for contracts that begin and end in the same fiscal year. Contract Costs The Company capitalizes costs to obtain contracts that are considered incremental and recoverable, such as sales commissions. The capitalized costs are amortized to selling, general and administrative expense over the estimated period of benefit of the asset, which is the contract term. The Company elected to use the practical expedient to expense the costs to obtain a contract when the amortization period is less than one year. The Company has contract costs of $0.2 million and $0.4 million capitalized at December 31, 2020 and December 31, 2019, respectively. Rental Income The Company also adopted ASC Topic 842, Leases The Company also derives income pursuant to product lease agreements for its Pharos laser systems, as operating leases. Consequently, the Company retains title to the equipment and the equipment remains on Company’s balance sheet within property and equipment. Depreciation expense on these leased lasers is recorded to cost of revenues on a straight-line basis. The costs to maintain these leased lasers are charged to cost of revenues as incurred. These lease arrangements contain one lease component (the laser) and one nonlease component (warranty service) for which the Company elected the practical expedient to not separate the nonlease component from the lease component. The Company accounts for the combined lease component as an operating lease and recognizes lease income on a straight-line basis over the lease term. Rental income from lease arrangements for the years ended December 31, 2020 and 2019 was $0.6 million and $0.7 million, respectively. Shipping and handling costs —Shipping and handling charged to customers is included in net product sales. Shipping and handling costs are included in selling, general and administrative expenses in the accompanying statements of operations. Shipping and handling costs were $0.1 million and $0.5 million for the years ended December 31, 2020 and 2019, respectively Advertising expense —The Company expenses advertising costs as incurred. There was no advertising expense for the year ended December 31, 2020. Advertising expense for the year ended December 31, 2019 was $0.1 million Research and development —Major components of research and development costs include personnel compensation expenses, stock-based compensation, consulting, materials and clinical trial expenses. Research and development expenses are charged to operations in the period they are incurred. Patents —The Company expenses patent costs, including related legal costs, as incurred and records such costs within selling, general and administrative expense in the accompanying statements of operations. Stock-based compensation — The Company evaluates whether an award should be classified and accounted for as a liability award or equity award for all stock-based compensation awards granted. There were no liability awards outstanding at December 31, 2020 or 2019. Stock-based compensation expense for equity instruments issued to employees and directors is measured based on estimating the fair value of each stock option on the date of grant using the Black Scholes option pricing model. Equity instruments issued to nonemployee consultants and service providers are valued using the Black Scholes option pricing model and are subject to revaluation as the underlying equity instruments vest. The Company recognizes forfeitures as they occur. The Company recognizes stock-based compensation expense as follows: Employees Nonemployees Service condition only Straight-line In the same period and in the same manner as if the Company paid cash for services. Performance criterion is probable of being met: Service criterion is complete Recognize the grant date fair value of the award once the performance criterion is considered probable of occurrence Recognize the grant date fair value of the award once the performance criterion is considered probable of occurrence Service criterion is not complete Straight-line Straight-line unless a performance condition is not probable Performance criterion is not probable of being met No expense is recognized until the performance criterion is considered probable, at which point expense is recognized per above No expense is recognized until the performance criterion is considered probable, at which point expense is recognized per above Income taxes —The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences reverse. Any resulting net deferred tax assets are evaluated for recoverability and, accordingly, a valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax asset will not be realized. The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining whether it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. An uncertain tax position is considered effectively settled on completion of an examination by a taxing authority if certain other conditions are satisfied. Should the Company incur interest and penalties relating to tax uncertainties, such amounts would be classified as a component of interest expense and other expense, respectively. Concentrations of credit risk —Credit risk represents the accounting loss that would be recognized at the reporting date if counterparties failed completely to perform as contracted. Concentrations of credit risk that arise from financial instruments exist for groups of customers or counterparties when they have similar economic characteristics that would cause their ability to meet contractual obligations to be similarly affected by changes in economic or other conditions described below. Financial instruments, which potentially subject the Company to concentration of credit risk, consist of cash, cash equivalents and short-term investments balances maintained in excess of Federal Depository Insurance Corporation limits, and accounts receivable which have no collateral or security. The Company monitors the financial condition of the banks in which it currently has deposits. The Company has not experienced any significant losses in this respect and believes that it is not exposed to any significant related risk. Exposure to losses on accounts receivable is dependent on the individual customer’s financial condition. The Company monitors its exposure to credit losses and reserves for those accounts receivable that it deems to be not collectible. No individual customer represented greater than 10% of total net revenue for the years ended December 31, 2020 and 2019. One individual customer represented 10% of accounts receivable for each of the years ended December 31, 2020 and 2019, respectively. Recently Adopted Accounting Pronouncements —As an emerging growth company, the Company may elect to adopt new or revised accounting standards when they become effective for non-public companies, which typically is later than public companies must adopt the standards. The Company has elected to take advantage of the extended transition period afforded by the JOBS Act and, as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-public companies, which are the dates included below. In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting . ASU 2018-07 expands the scope of Topic 718, Compensation—Stock Compensation , to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. ASU 2018-07 supersedes Subtopic 505-50, Equity—Equity-Based Payments to Non-Employees . The amendments are effective for fiscal years beginning after December 15, 2019. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The Company adopted this guidance on January 1, 2020 and there was no impact on the financial statements and related disclosures. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), to require the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts and applies to all financial assets, including trade receivables. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. ASU No. 2016-13 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted this guidance on January 1, 2020 and there was no material impact on the financial statements.

Short-term Investments

Short-term Investments	12 Months Ended
	Dec. 31, 2020
Short Term Investments [Abstract]
Short-term Investments	Note 3—Short-term Investments A summary of debt securities by major security type is as follows as of December 31, 2019 (in thousands): Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Debt Securities-available-for-sale: U.S. agency securities $ 1,000 $ — $ — $ 1,000 U.S. government securities 14,967 26 — 14,993 Total debt securities $ 15,967 $ 26 $ — $ 15,993 All debt securities were due in less than one year. The following table presents the hierarchy for assets measured at fair value on a recurring basis (in thousands): Total Fair Value Quoted Market Prices for Identical Assets (Level 1) Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) As of December 31, 2020 Money market funds $ 18,394 $ 18,394 $ — $ — As of December 31, 2019 Money market funds $ 13,219 $ 13,219 $ — $ — U.S. government securities $ 14,993 $ 14,993 $ — $ — U.S. agency securities $ 1,000 $ — $ 1,000 $ —

Inventories

Inventories	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Inventories	Note 4—Inventories Inventories consisted of the following (in thousands): December 31, 2020 2019 Raw materials $ 1,739 $ 2,300 Work in process 270 215 Finished goods 209 262 Inventories $ 2,218 $ 2,777

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2020
Property Plant And Equipment Net [Abstract]
Property and Equipment, Net	Note 5—Property and Equipment, net Property and equipment consisted of the following (in thousands): December 31, 2020 2019 Lasers $ 4,677 $ 4,671 Machinery and equipment 866 841 Automobiles 1,054 1,109 Computer hardware and software 353 348 Leasehold improvements 119 119 Furniture and fixtures 48 48 Construction in progress 51 23 Property and equipment, gross 7,168 7,159 Accumulated depreciation (3,957 ) (2,109 ) Property and equipment, net $ 3,211 $ 5,050 Depreciation expense was $2.0 million and $1.4 million for the years ended December 31, 2020 and 2019, respectively.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2020
Payables And Accruals [Abstract]
Accrued Expenses	Note 6—Accrued Expenses Accrued expenses consisted of the following (in thousands): December 31, 2020 2019 Compensation and related benefits $ 2,602 $ 1,163 Accrued warranty (Note 7) 242 338 Accrued services 1,504 1,141 Accrued expenses $ 4,348 $ 2,642

Accrued Warranty

Accrued Warranty	12 Months Ended
	Dec. 31, 2020
Product Warranties Disclosures [Abstract]
Accrued Warranty	Note 7—Accrued Warranty Activity in the product warranty accrual is included in accrued expenses above and consists of the following (in thousands): Year ended December 31, 2020 2019 Balance at beginning of period $ 338 $ 112 Increase in warranty accrual 87 889 Change in liability for pre-existing warranties (2 ) (28 ) Claims satisfied (181 ) (635 ) Accrued warranty $ 242 $ 338 Warranty expense was $0.1 million and $0.9 million for the years ended December 31, 2020 and 2019, respectively. The accrued warranty balances at December 31, 2020 and 2019 include $0.1 million and $0.2 million, respectively, relating to the voluntary recall of catheters, which was initiated in September 2019. Warranty expense is included in cost of revenue in the accompanying statements of operations.

Paycheck Protection Program Pro

Paycheck Protection Program Promissory Note	12 Months Ended
	Dec. 31, 2020
Paycheck Protection Program Promissory Note [Abstract]
Paycheck Protection Program Promissory Note	Note 8—Paycheck Protection Program Promissory Note In May 2020, the Company entered into a $2.0 million Paycheck Protection Program Promissory Note and Agreement (“PPP Promissory Note”) with a commercial bank under the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act. The PPP Promissory Note bears interest at 1.0% per annum. Under the terms of the PPP Promissory Note, payments would be due monthly beginning November 1, 2020 and the principal amount of the PPP Promissory Note along with any unpaid interest would be due on May 3, 2022. On June 5, 2020, the Paycheck Protection Program Flexibility Act of 2020 (the “PPPFA”) extended the deferral period for all loans to 10 months after the last day of the covered period. Under the revised terms, payments are due beginning August 2021 and the principal amount along with unpaid interest is due in May 2022. The Company has requested from its lender an extension of the loan maturity from two years to five years as permitted under the PPPFA. The principal and interest may be forgiven if the proceeds are used for forgivable purposes as defined by the terms in the PPP Promissory Note, and the Company believes it has used the proceeds from the PPP Promissory Note for forgivable purposes as defined by the terms of the PPP Promissory Note. The Company intends to apply for forgiveness under the provisions of the CARES Act. Forgiveness is subject to the sole approval of the Small Business Administration. Interest expense for the year ended December 31, 2020 was $13,000.

Leases

Leases	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Leases	Note 9—Leases The Company recognized non-cash right-of-use assets and lease liabilities of $3.2 million upon adoption of ASU 2016-02 on January 1, 2019. The Company has two operating leases for office and manufacturing space which requires it to pay base rent and certain utilities. Monthly rent expense is recognized on a straight-line basis over the terms of the leases, which expire in 2027 and 2021. At December 31, 2020 the weighted average remaining lease term was seven years. The operating leases are included in the balance sheet at the present value of the lease payments at a 7% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the leases do not provide an implicit rate. For the years ended December 31, 2020 and 2019, operating lease expense and cash paid were each $0.5 million. Operating lease right-of-use assets amortization was $0.4 million and $0.3 million for the years ended December 31, 2020 and 2019, respectively. Variable costs are de minimis. The following table presents the lease liabilities within the balance sheet, related to the Company’s operating leases as of December 31, 2020 (in thousands): Years Ending December 31, 2021 $ 528 2022 432 2023 445 2024 459 2025 472 Thereafter 987 Total operating lease payments $ 3,323 Less: imputed interest (703 ) Total operating lease liabilities $ 2,620

Equipment Financing

Equipment Financing	12 Months Ended
	Dec. 31, 2020
Equipment Financing [Abstract]
Equipment Financing	Note 10—Equipment Financing During 2018, the Company entered into four loan agreements to finance 25 automobiles. The loans mature in 2021 and bear interest at a weighted average interest rate of 6.5%. These loans are secured by the automobiles. Interest expense for the years ended December 31, 2020 and 2019 was $28,000 and $48,000, respectively. The outstanding balance at December 31, 2020 was $0.3 million and included in equipment financing. The loans were repaid in March 2021.

Loss per Share

Loss per Share	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Loss per Share	Note 11—Loss per Share The Company calculates basic loss per share by dividing net loss by the weighted average number of common shares outstanding during the reporting period. A net loss cannot be diluted, so when the Company is in a net loss position, basic and diluted loss per common share are the same. If in the future the Company achieves profitability, the denominator of a diluted earnings per common share calculation will include both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and non-vested restricted stock awards and units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The Company’s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company. Anti-dilutive common share equivalents excluded from the computation of diluted net loss per share at December 31, 2020 consisted of warrants of 2,345,033, stock options of 142,171, restricted stock units of 33,548, restricted stock awards of 290,536 and Employee Stock Purchase Plan shares of 3,200. Anti-dilutive common share equivalents excluded from the computation of diluted net loss per share at December 31, 2019 consisted of stock options of 125,579, restricted stock units of 10,864 and Employee Stock Purchase Plan shares of 2,473.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2020
Stockholders Equity [Abstract]
Stockholders' Equity	Note 12—Stockholders’ Equity Common stock — In May 2020, the Company completed a public offering (the “May 2020 Offering”) of an aggregate of 888,888 shares of common stock, together with accompanying warrants to purchase up to an aggregate of 888,888 shares of common stock, at a public offering price of $11.25 per share and accompanying warrant. Each share of common stock was sold in the offering with one warrant to purchase one share of common stock. The warrants have an exercise price of $11.25 per share, are immediately exercisable, and expire five years following the date of issuance. Placement agent warrants were issued to purchase up to an aggregate of 62,222 shares of common stock, are immediately exercisable for an exercise price of $14.0625, and expire five years following the date of issuance. The Company received approximately $8.7 million in net proceeds, after deducting placement agent’s fees and other offering expenses of $1.3 million payable by it The warrants and placement agent warrants were valued at an aggregate $3.5 million using the Black-Scholes option pricing model based on the following assumptions; expected volatility 59.86%, risk-free interest rate 0.34%, expected dividend yield 0.00% and an expected term of 2.5 years. In June 2020, the Company issued 73,506 shares of common stock in connection with the exercise of warrants issued in the May 2020 Offering. At December 31, 2020, the Company had 815,382 In August 2020, the Company completed another public offering (the “August 2020 Offering”) of an aggregate of 1,371,429 shares of common stock, together with accompanying warrants to purchase up to an aggregate of 1,371,429 shares of common stock, at a public offering price of $ 8.75 per share and accompanying warrant. Each share of common stock was sold in the offering with one warrant to purchase one share of common stock. The warrants have an exercise price of $ 8.75 per share, are immediately exercisable, and expire five years following the date of issuance. Placement agent warrants were issued to purchase up to an aggregate of 96,000 , are immediately exercisable for an exercise price of $10 .9375 , and expire five years following the date of issuance. The Company received approximately $10.4 million in net proceeds, after deducting placement agent’s fees and other estimated offering expenses of $1.6 million payable by it The warrants and placement agent warrants were valued at an aggregate $4.0 million using the Black-Scholes option pricing model based on the following assumptions; expected volatility 59.72%, risk-free interest rate 0.17%, expected dividend yield 0.00% and an expected term of 2.5 years. At December 31, 2020, the Company had 1,371,429 Preferred stock — At December 31, 2020 and 2019, the Company has no shares of preferred stock outstanding

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	Note 13—Stock-Based Compensation On June 4, 2018, the 2018 Stock Compensation Plan was established (the “Compensation Plan”) whereby 132,000 shares of the Company’s common stock were reserved for issuance. On June 4, 2018, the Company’s board of directors authorized 76,076 replacement equity awards of stock options for awards that had been granted under a previous plan, and, on June 8, 2018, 53,633 restricted stock units (collectively, the “Replacement Awards”) to eligible employees, directors, consultants and service providers. Stock options granted under the Compensation Plan, including those granted as a component of the Replacement Awards, generally vest 33% on the first anniversary of the grant date with the balance vesting monthly over the remaining two years. The restricted stock units granted under the Compensation Plan, including those granted as a component of the Replacement Awards, include a service condition and a performance condition. The service condition generally begins on the grant date and continues through January 2020 and the restricted stock units vest at various times commencing March 27, 2019 until January 2020. The performance condition related to the Company completing its IPO and the vesting of the restricted stock units were contingent upon the achievement of such IPO, which was achieved on October 1, 2018. The restricted stock units granted under the Compensation Plan, including those granted as a component of the Replacement Awards, include a service condition and a performance condition. The service condition generally begins on the grant date and continues through January 2020 and the restricted stock units vest at various times commencing the day following the expiration of the lock-up until January 2020. The performance condition related to the Company completing its IPO and the vesting of the restricted stock units were contingent upon the achievement of such IPO, which was achieved on October 1, 2018. Stock options granted under the 2018 Plan generally vest 25% on the first anniversary of the vesting commencement date with the balance vesting monthly over the remaining three years. Restricted stock units granted under the 2018 plan generally have a vesting schedule with one third of the total number of shares underlying the restricted stock units vesting on the first anniversary of the vesting commencement date and one sixth of the total shares vesting every six months thereafter such that the award will be fully vested on the third anniversary of the vesting commencement date. In September 2018, the Company’s board of directors adopted, and the Company’s stockholders approved, the Company’s 2018 Equity Incentive Plan (the “2018 Plan”). As of December 31, 2020, 110,329 shares of common stock are reserved for future issuance pursuant to the Company’s 2018 Plan. In addition, the shares reserved for issuance under the 2018 Plan include (1) those shares reserved but unissued under the Compensation Plan as of the date of stockholder approval of the 2018 Plan and (2) shares of common stock subject to or issued pursuant to awards granted under the Compensation Plan that, after the date of stockholder approval of the 2018 Plan, expire or otherwise terminate without having been exercised in full or are forfeited to or repurchased by us (provided that the maximum number of shares that may be added to the 2018 Plan pursuant to (1) and (2) is 132,000 shares). The 2018 Plan provides for the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code to the Company’s employees and any of the Company’s parent and subsidiary corporations’ employees, if applicable, and for the grant of nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to the Company’s employees, directors and consultants and the Company’s parent and subsidiary corporations’ employees, if applicable, and consultants. In March 2020 the Company adopted the 2020 Inducement Equity Incentive Plan (the “2020 Plan”) with the purpose of attracting, retaining and incentivizing employees in furtherance of the Company’s success. The 2020 Plan was adopted without stockholder approval pursuant to Rule 303A.08 of the New York Stock Exchange rules. In accordance with New York Stock Exchange rules, this plan is used to offer equity awards as material inducements for new employees to join the Company. On adoption, 32,000 shares of common stock were reserved solely for the granting of inducement stock options, restricted stock, restricted stock units and other awards. The 2020 Plan provides for the granting of stock options with exercise prices equal to the fair market value of our common stock on the date of grant. During the year ended December 31, 2020 there were 18,000 stock options granted with a weighted average exercise price of $25.50. There are 3,375 exercisable options in the 2020 Plan at December 31, 2020. During the year ended December 31, 2020, 5,000 restricted stock awards were granted, of which 625 vested, with a grant date fair value of $0.1 million, under the 2020 Plan. A summary of the activity and related information of the stock options issued under the 2018 Equity Incentive Plan and the Compensation Plan is presented below: Stock Options Weighted Average Exercise Price Weighted Average Remaining Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2018 76,804 $ 714.75 9.43 $ — Granted 60,854 30.50 Forfeited (12,079 ) 670.25 Outstanding at December 31, 2019 125,579 $ 387.50 9.43 $ — Granted 11,729 30.69 Forfeited (13,137 ) 297.57 Outstanding at December 31, 2020 124,171 $ 363.31 6.42 $ — Exercisable at December 31, 2020 84,376 $ 466.78 5.89 $ — Vested and expected to vest at December 31, 2020 124,171 $ 363.31 6.42 $ — A summary of the activity and related information of the restricted stock units is presented below: Restricted Stock Units Weighted Average Grant Date Fair Value Outstanding at December 31, 2018 59,767 $ 672.75 Granted 12,010 98.75 Vested and released (48,269 ) 698.25 Forfeited (12,644 ) 497.75 Outstanding at December 31, 2019 10,864 $ 128.82 Granted 32,019 10.82 Vested and released (7,906 ) 114.55 Forfeited (1,429 ) 101.79 Outstanding at December 31, 2020 33,548 $ 21.93 A summary of the activity and related information of the restricted stock awards is presented below: Restricted Stock Awards (in shares) Weighted Average Grant Date Fair Value Outstanding at December 31, 2019 — $ — Granted 286,161 4.77 Forfeited — — Vested — — Outstanding at December 31, 2020 286,161 $ 4.77 Stock-based compensation expense recorded in operating expenses was as follows (in thousands): Year Ended December 31, 2020 2019 Selling, general and administrative $ 3,302 $ 20,392 Research and development 447 1,537 Stock-based compensation in operating expenses $ 3,749 $ 21,929 Stock-based compensation amounts of $0.3 million and $1.6 million were capitalized to property and equipment and inventory during the years ended December 31, 2020 and 2019, respectively. Unrecognized compensation expense for stock options issued as of December 31, 2020 was $1.8 million and is expected to be recognized over a weighted-average period of 1.2 years. Unrecognized compensation expense for the restricted stock units as of December 31, 2020 was $0.6 million and is expected to be recognized over a weighted-average period of 1.9 years. Unrecognized compensation expense for the restricted stock awards as of December 31, 2020 was $1.4 million and is expected to be recognized over a weighted-average period of 2.8 years. The fair value of the stock options issued under the 2018 Plan was estimated using the Black Scholes option pricing model and the weighted-average assumptions used in the model are noted in the following table: Year Ended December 31, 2020 2019 Risk-free interest rate 1.3 % 1.6 % Volatility 58.96 % 59.26 % Expected dividend yield 0.00 % 0.00 % Expected life (in years) 5.8 5.9 The fair value of the stock options issued under the 2020 Plan was estimated using the Black Scholes option pricing model and the weighted-average assumptions used in the model are noted in the following table: Year Ended December 31, 2020 Risk-free interest rate 0.5 % Volatility 58.33 % Expected dividend yield 0.00 % Expected life (in years) 6.3 The Company’s 2018 Employee Stock Purchase Plan (ESPP) became effective in September 2018. A total of 19,463 shares of common stock were available for sale under our ESPP as of December 31, 2020. Under the Company’s ESPP, eligible employees are allowed to purchase the Company’s stock at a discounted price, which is 85% of the lower market price of the Company’s common stock at the beginning or at the end of the six-month purchase period. The Company issued 5,278 and 368 shares in exchange for $42,000 and $37,000 in the and 2019, respectively, under the ESPP.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Note 14—Income Taxes A reconciliation of the differences between the United States statutory federal income tax rate and the effective tax rate as provided in the statements of operations is as follows: Year Ended December 31, 2020 2019 Tax computed at the federal statutory rate 21.0 % 21.0 % State income taxes, net of federal benefits 5.1 1.9 Nondeductible expenses (0.1 ) (0.4 ) Stock-based compensation (2.2 ) (9.5 ) Deferred tax adjustments (57.0 ) — Change in valuation allowance 33.2 (13.0 ) — — The federal and state income tax provision is summarized as follows (in thousands): Year Ended December 31, 2020 2019 Current Federal $ — $ — State 7 15 7 15 Deferred Federal — — State — — — — Income tax expense $ 7 $ 15 Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for tax purposes, and (b) operating losses and tax credit carryforwards. The tax effects of significant components of the Company’s deferred tax assets (liabilities) are as follows (in thousands): December 31, 2020 2019 Deferred Tax Assets: Net operating loss carryforwards $ 3,720 $ 16,096 Operating lease liabilities 691 766 Other accruals 101 61 Accrued compensation 448 — Reserves 299 301 Deferred revenue 642 850 Intangible assets 32 253 Stock-based compensation 4,910 4,821 Total gross deferred tax assets $ 10,843 $ 23,148 Deferred Tax Liabilities: Property and equipment (805 ) (1,026 ) Operating lease right-of-use assets (655 ) (739 ) Other (61 ) (92 ) Total gross deferred tax liabilities $ (1,521 ) $ (1,857 ) Valuation allowance (9,322 ) (21,291 ) Total deferred taxes $ — $ — At December 31, 2020, the Company had available federal and state net operating loss carryforwards of approximately $14.3 million and $13.4 million, respectively, which may be used to offset future federal and state taxable earnings. The federal net operating loss can be carried forward indefinitely and the state net operating losses begin expiring in 2032. Use of these net operating loss carryforwards may be significantly limited under the tax rules regarding the use of losses following an ownership change under Internal Revenue Code (“IRC”) Section 382. The Company has completed an IRC Section 382 analysis regarding the limitation of net operating losses through December 31, 2020 and determined that an ownership change occurred in May 2020. The Company calculated the limitation on net operating losses and other tax attributes and reduced the value of the deferred tax assets resulting in a tax expense impact of $20.8M. The tax expense was offset by tax benefit recorded on the reduction in valuation allowance recorded for the deferred tax assets for the year ended December 31, 2020. As of December 31, 2020, the Company does not have any unrecognized tax benefits. The Company does not anticipate that the amount of unrecognized tax benefits will significantly increase in the next 12 months. There were no interest and penalties accrued as of December 31, 2020. The Company files U.S. federal and various states income tax returns, which are subject to examination by the taxing authorities for years 2016 and later. However, the federal net operating loss carryover may be adjusted three years from the date the loss is utilized on an income tax return. ASC 740, Income Taxes On March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748) which includes a number of provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. Under ASC 740, the effects of new legislation are recognized upon enactment. Accordingly, the effects of the CARES Act have been incorporated into the income tax provision computation for the year ended December 31, 2020. These provisions did not have a material impact on the income tax provision. The Consolidated Appropriations Act, 2021 (CAA 2021), which was signed into law on December 27, 2020, provided that deductions are allowed for otherwise deductible expenses paid with the proceeds of a Paycheck Protection Program (PPP) loan that is forgiven and that the tax basis and other attributes of the borrower’s assets will not be reduced as a result of the loan forgiveness. Prior to the enaction of the CCA, the deductions paid with proceeds of a PPP loan that was forgiven were not allowed. These provisions did not have a material impact on the income tax provision.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 15—Commitments and Contingencies Legal —In the normal course of business, the Company is at times subject to pending and threatened legal actions. In management’s opinion, any potential loss resulting from the resolution of these matters will not have a material effect on the results of operations, financial position or cash flows of the Company. Securities Litigation On June 7, 2019, a putative securities class action complaint captioned Derr v. Ra Medical Systems, Inc., et. al., between September 27, 2018 and November 27, 2019, inclusive, in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The Company is unable to predict the ultimate outcome and is unable to make a meaningful estimate of the amount or range of loss, if any, that could result from any unfavorable outcome. On October 1, 2019, a shareholder derivative complaint captioned Noel Borg v. Dean Irwin, et. al On October 21, 2019, pursuant to the parties’ stipulation, the court stayed the derivative lawsuit until the related class action is resolved The Company is unable to predict the ultimate outcome and is unable to make a meaningful estimate of the amount or range of loss, if any, that could result from any unfavorable outcome. Government Investigations As previously announced in the Form 8-K filed on August 12, 2019, the Audit Committee of the Company’s Board of Directors (the “Audit Committee”) conducted an investigation of certain allegations raised by a former employee. The Company announced the Audit Committee’s findings in the Form 8-K filed on October 31, 2019. The primary investigative findings were: (i) the DABRA catheter frequently failed to calibrate and occasionally overheated, posing a risk of injury to physicians and patients; (ii) the Company’s explanations regarding its fourth quarter 2018 and first quarter 2019 sales created a risk of confusion because they did not explicitly reference inconsistent DABRA catheter performance and catheter failures; (iii) the Company failed to timely make at least two Medical Device Reports, or MDRs, to the FDA; (iv) the Company, out of a concern for the DABRA catheters’ performance, engaged in systematic efforts to replace product held by customers, which constituted product recalls, but were not documented as such, (v) the Company lack documentation of sufficient detail and specificity to support certain payments to physicians, ostensibly for training and consulting services, and as to three physicians did not accurately reflect the purpose and nature of approximately $300,000 of payments, which could be perceived as an improper attempt to obtain business or to gain special advantage, (vi) while the indication for use in the 510(k) clearance the Company obtained for the DABRA system is not for atherectomy, the Company’s salespeople were instructed to characterize DABRA as performing atherectomy and to encourage doctors to seek reimbursement using atherectomy codes, (vii) the Company’s determinations to direct potentially valuable benefits and opportunities to doctors were informed in part by sales prospects, and (viii) the Company received complaints regarding regulatory or compliance concerns that, because they implicated executive officers, should have been brought to the attention of the Board or the Audit Committee, but were not. On December 28, 2020, the Company entered into a Settlement Agreement with the United States of America, acting through the DOJ and on behalf of the OIG, to resolve the pending DOJ investigation and a related civil action concerning our marketing of the DABRA laser system and DABRA-related remuneration to certain physicians. In connection with the Settlement Agreement, the Company also has reached tentative agreements that, if executed by participating states, resolve previously disclosed related investigations conducted by certain state attorneys general. The Settlement Agreement recites that a complaint filed by a former employee on behalf of the federal government in the United States District Court for the Eastern District of Michigan, and subsequently amended to assert claims on behalf of certain states, alleged, among other things, that the Company violated the False Claims Act, 31 U.S.C. § 3729, and certain state false claims acts by paying kickbacks to certain physicians in order to induce them to use the DABRA laser system, promoting off-label use of the DABRA laser system, failing to report adverse events to the United States Food and Drug Administration, marketing a device that does not work as advertised, and failing to adhere to Current Good Manufacturing Practices. The complaint, which was settled in connection with the Settlement Agreement, also alleged that we unlawfully retaliated against the former employee. Under the Settlement Agreement, and the tentative agreements with the participating states, the Company is required to make an initial payment of $2.5 million, of which the Company paid $2.4 million in December 2020 and will pay the remaining $0.1 million when the agreements with the participating states are finalized. Pursuant to the terms of the Settlement Agreement, (a) if its revenue exceeds $10 million in any of the next four fiscal years (2021-2024), it also is required to pay an additional amount in settlement for the corresponding year: $500,000 for 2021, $750,000 for 2022, $1 million for 2023, and $1.25 million for 2024; (b) if it is acquired or is otherwise involved in a change in control transaction in the years 2020 through 2024, it is required to pay an additional settlement amount of $5 million, plus 4% of the value attributed to the Company in the transaction, so long as the attributed value is in excess of $100 million, with the total change in control payment never to exceed $28 million; and (c) if its obligations under the Settlement Agreement are avoided by bankruptcy, the United States may rescind the releases and bring an action against the Company in which the Company agrees is not subject to an automatic stay, is not subject to any statute of limitations, estoppel or laches defense, and is a valid claim in the amount of $56 million, minus any prior change in control payments. Under the Settlement Agreement, the Company also paid the former employee’s reasonable expenses, costs and attorneys’ fees, which amount to $0.2 million. The Company has expensed $2.7 million and has remaining accrued expenses of $0.3 million at December 31, 2020 relating to this matter. The OIG has agreed, conditioned upon our full payment of amounts owed in the Settlement Agreement, and in consideration of the Company’s obligations under a Corporate Integrity Agreement, to release its permissive exclusion rights and refrain from instituting any administrative action seeking to exclude it from participating in Medicare, Medicaid, or other federal health care programs as a result of the Covered Conduct. The Corporate Integrity Agreement has a five-year term and imposes monitoring, reporting, certification, documentation, oversight, screening, and training obligations on the Company, including the hiring of a compliance officer and independent review organization. Pursuant to the terms of the Settlement Agreement, the United States and the former employee have dismissed the complaint against the Company with prejudice, and have released the Company from any civil or administrative monetary liability arising under the Covered Conduct. The Settlement Agreement does not include a release for any conduct other than the Covered Conduct or any criminal liability related to the Covered Conduct. The Settlement Agreement does not release any claims under investigation by the SEC. As also previously announced, the Company voluntarily contacted the SEC’s Enforcement Division regarding the Audit Committee’s investigation. On November 13, 2019, the SEC notified the Company that it is conducting an investigation. The Company has been, and intends to continue, cooperating with the SEC in this ongoing investigation. The Company is unable to predict the ultimate outcome and is unable to make a meaningful estimate of the amount or range of loss, if any, that could result from any unfavorable outcome. On November 21, 2019, the Company became aware that the Criminal Division, Fraud Section of the DOJ has an open investigation related to the Company. At this time, it is unclear if the Company is a target in this investigation. The Company has been, and intends to continue, cooperating with the DOJ in its active and ongoing investigation. The Company is unable to predict the ultimate outcome and is unable to make a meaningful estimate of the amount or range of loss, if any, that could result from any unfavorable outcome. Other Litigation On August 30, 2018, Strata Skin Sciences, Inc. (“Strata”) and Uri Geiger, a member of the board of directors of Strata Skin Sciences, Inc. (collectively “Strata”) filed an action against the Company in Court of Common Pleas of, Montgomery County, Pennsylvania (Civil Action No. 18-21421) (the “Pennsylvania Case”), requesting declaratory relief that: (1) Strata and Mr. Geiger are not liable for tortious interference, defamation, libel, or unfair competition based on an e-mail by Mr. Geiger to an investment bank (the “Geiger Email”); (2) Strata and Mr. Geiger made no actionable statements about the Company to such investment bank; (3) the Company cannot enforce the 2011 settlement and release agreement between the Company and PhotoMedex, Inc. (“Settlement Agreement”) against Strata; and (4) that any dispute regarding the Geiger Email does not relate to the Settlement Agreement. The action filed by Strata and Mr. Geiger does not request any monetary damages. On May 16, 2019, the Company filed an action against Strata, Mr. Geiger and Accelmed Growth Partners, L.P. (collectively, the “Strata Parties”) in the United States District Court for the Southern District of California (Civil Action No. 19-cv-0920-AJB-MSB (the “California Case”)) alleging (1) breach of the Settlement Agreement, (2) intentional interference in contractual relations, (3) intentional interference in prospective economic relations, and (4) trade libel. In the California Case, the Company alleges, among other things, that the statements in the Geiger Email regarding alleged patent infringement constitute a breach of the Settlement Agreement, that the Strata Parties employed deceptive practices designed to delay the Company’s initial public offering and reduce the amount of capital raised by the Company, and that statements in the Geiger Email regarding patent infringement, off label promotion and reimbursement constitute trade libel. On August 11, 2020, the Company and the Strata Parties executed a settlement agreement, dated as of August 6, 2020, that includes a mutual release of claims and an agreement to terminate the Pennsylvania Case and the California Case. On February 12, 2020, Dean Irwin, the Company’s former Chief Executive Officer, filed a Demand for Arbitration, alleging that the Company attempted to coerce him into signing a non-standard separation agreement and release of claims, contrary to the terms of his Severance Agreement. Mr. Irwin claims that he was willing to sign the Company’s standard separation agreement and release of claims. Based on this allegation, Mr. Irwin is claiming nonpayment of wages, penalties for nonpayment of wages, failure to provide wage statements, breach of contract, and breach of implied covenant of good faith and fair dealing. On December 21, 2020, the arbitrator granted summary judgment in favor of the Company on four of the five issues raised by Mr. Irwin in the arbitration. The Company and Mr. Irwin executed a settlement agreement, effective as of January 19, 2021, whereby the Company paid Mr. Irwin $265,000 in exchange for a mutual release of claims and dismissal of the arbitration. The Company has accrued this settlement amount at December 31, 2020. 401(k) — In January 2019, the Company established a defined contribution plan under Section 401(k) of the Internal Revenue Code (“401(k) Plan”) that the Company administers for participating employees’ contributions.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Segment Information	Note 16—Segment Information The Company has organized its business into two operating segments based on the product specialties: the vascular segment and the dermatology segment. In deciding how to allocate resources and assess performance, the Company’s chief operating decision maker regularly evaluates the sales and gross profit of these segments. Amounts included within selling, general and administrative expense and research and development expense are general to the Company and not specific to a particular segment; therefore, these amounts are not evaluated by the Company’s chief operating decision maker on a segmented basis. The following tables summarize segment performance (in thousands): Year Ended December 31, 2020 2019 Vascular $ 259 $ 1,275 Dermatology 4,146 5,924 Net revenue $ 4,405 $ 7,199 Vascular $ 1,970 $ 4,036 Dermatology 3,512 4,814 Cost of revenue $ 5,482 $ 8,850 Vascular $ (1,711 ) $ (2,761 ) Dermatology 634 1,110 Gross (loss) profit $ (1,077 ) $ (1,651 ) Generally, all assets are common assets, except for lasers, which are a subset of property and equipment. The net book value of the lasers aggregated in the vascular segment was $1.9 million and $2.6 million as of December 31, 2020 and 2019, respectively. The net book value of the lasers placed with customers aggregated in the dermatology segment was $0.7 million and $0.9 million as of December 31, 2020 and 2019, respectively. Net revenue, classified by the major geographic areas in which our customers are located, was as follows (in thousands): Year Ended December 31, 2020 2019 United States $ 4,181 $ 6,568 All other countries 224 631 Net revenue $ 4,405 $ 7,199

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Use of Estimates	Use of estimates —The financial statements of the Company have been prepared by management in accordance with accounting principles generally accepted in the United States of America. The preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and reported disclosures of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. The Company’s financial statements are based upon a number of estimates, including but not limited to, allowance for doubtful accounts, reserves for warranty costs including product recalls, evaluation of probable loss contingencies, fair value of stock option awards granted and revenue recognition for multiple performance obligations.
Short-term Investments	Short-term Investments — I nvestments with original maturities of greater than three months are classified as short-term investments. Debt investments are classified as available-for-sale and realized gains and losses are recorded using the specific identification method. Changes in fair value, excluding other-than-temporary impairments, are recorded in other comprehensive income (“OCI”). Debt investments are impaired when a decline in fair value is judged to be other-than-temporary. Fair value is calculated based on publicly available market information or other estimates determined by management. The Company employs a systematic methodology on a quarterly basis that considers available quantitative and qualitative evidence in evaluating potential impairment of our investments. If the cost of an investment exceeds its fair value, the Company evaluates, among other factors, general market conditions, credit quality of debt instrument issuers, and the duration and extent to which the fair value is less than cost. The Company also evaluates whether it has plans to sell the security or it is more likely than not that the Company will be required to sell the security before recovery. In addition, the Company considers specific adverse conditions related to the financial health of and business outlook for the investee, including industry and sector performance, changes in technology, and operational and financing cash flow factors. Once a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in other income (expense), net and a new cost basis in the investment is established.
Fair Value Measurements	Fair value measurements — Fair value represents the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants and is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier value hierarchy is used to identify inputs used in measuring fair value as follows: Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets. Level 2—Inputs other than the quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. The hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company measures its cash and cash equivalents and short-term investments at fair value.
Fair Value of Financial Instruments	Fair value of financial instruments —Cash and cash equivalents, trade accounts receivable, accounts payable, accrued expenses, deferred revenue and other current assets and liabilities are reported on the balance sheets at carrying value which approximates fair value due to the short-term maturities of these instruments. The fair value of the Company’s debt, which is classified as equipment financing liability on the balance sheets, is estimated based on current rates offered to the Company for similar debt and approximates carrying value.
Cash and Cash Equivalents	Cash and cash equivalents —The Company considers all short-term, highly liquid investments with original maturities of three months or less to be cash equivalents. Cash equivalents primarily represent funds invested in readily available checking and money market accounts. The Company maintains deposits in financial institutions in excess of federally insured limits.
Accounts Receivable, Net	Accounts receivable, net —Trade accounts receivable are presented net of allowances for doubtful accounts. The Company sells or leases its lasers to distributors or physicians directly with various forms of financing options. The Company extends credit based on an evaluation of the customers’ financial condition generally without requiring collateral. Exposure to losses on trade receivables is expected to vary by customer due to the financial condition of each customer. The Company monitors exposure to credit losses and maintains allowances for anticipated losses considered necessary under the circumstances. The Company maintains an allowance for doubtful accounts for balances that appear to have specific collection issues and expected credit losses. The collection process is based on the age of the invoice and requires attempted contacts with the customer at specified intervals. If, after a specified number of days, the Company has been unsuccessful in its collection efforts, provision for doubtful accounts is recorded for the balance in question. Delinquent accounts receivable are charged against the allowance for doubtful accounts once the Company has determined the amounts are uncollectible. The factors considered in reaching this determination are the apparent financial condition of the customer and the Company’s success in contacting and negotiating with the customer. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. The following table shows the allowance for doubtful accounts activity (in thousands): Year Ended December 31, 2020 2019 Balance at beginning of period $ 355 $ 214 Provision for doubtful accounts 180 283 Deductions (264 ) (142 ) Balance at end of period $ 271 $ 355
Inventories	Inventories —Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. Cost includes materials, labor and manufacturing overhead related to the purchase and production of inventories. The Company reduces the carrying value of inventories for those items that are potentially excess, obsolete or slow-moving based on changes in customer demand, technological developments or other economic factors. Catheters are manufactured in-house and each catheter is tested at various stages of the manufacturing process for adherence to quality standards. Catheters that do not meet functionality specification at each test point are destroyed and immediately written off, with the expense recorded in cost of revenue in the statements of operations. Once manufactured, completed catheters that pass quality assurance, are sent to a third-party for sterilization and sealed in a sterile container. Upon return from the third-party sterilizer, a sample of catheters from each batch are re-tested. If the sample tests are successful, the batch is accepted into finished goods inventory and if the sample tests are unsuccessful, the entire batch is written off, with the expense recorded in cost of revenue in the statements of operations.
Property and Equipment, Net	Property and equipment, net —Property and equipment are recorded at cost and are depreciated on a straight-line basis over their estimated useful lives as follows: Computer hardware and software 4-5 years Furniture and fixtures 5 years Machinery and equipment 5-10 years Lasers 3-5 years Automobiles 5 years Leasehold improvements are depreciated over the shorter of the useful life of the leasehold improvement or the term of the underlying property’s lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the account balances and any resulting gain or loss is recognized in income for the period. The cost of repairs and maintenance is expensed as incurred, whereas significant betterments are capitalized.
Impairment of Long-lived Assets	Impairment of long-lived assets —The Company periodically reviews its long-lived assets for impairment when certain events or changes in circumstances indicate that the carrying value of the long-lived assets may not be recoverable. Should the sum of the undiscounted expected future net cash flows be less than the carrying value, the Company would recognize an impairment loss at that date. The inconsistencies in the DABRA catheter performance, the voluntary product recall and the reduction in the sales force resulted in lower current and expected revenues for the vascular segment, led the Company to accelerate its annual testing for asset impairment into the third quarter of 2019. There were no impairment charges for the years ended December 31, 2020 or 2019.
Product Warranty	Product warranty —The Company records estimated product warranty costs at the time of sale. Products are warrantied against defects in material and workmanship when properly used for their intended purpose and appropriately maintained. Accordingly, the Company generally replaces catheters that kink or fail to calibrate. The product warranty liability is determined based on historical information such as past experience, product failure rates or number of units repaired, estimated cost of material and labor. The product warranty liability also includes the estimated costs of a product recall. Product warranties are included for the first year after the sale for laser sales. For lasers, the customer may purchase an extended service contract, which is either negotiated in the contract or sold as a separate component for which revenue is recognized over the term of the agreement. The warranty accrual is included in accrued expenses in the accompanying balance sheets. Warranty expenses are included in cost of revenue in the accompanying statements of operations. Changes in estimates to previously established warranty accruals result from current period updates to assumptions regarding repair and product recall costs and are included in current period warranty expense.
Revenue Recognition	Revenue recognition —The Company adopted ASC Topic 606 (Topic 606), Revenue from Contracts with Customers , on January 1, 2019 using the modified retrospective method to all contract agreements not completed as of January 1, 2019. Results for reporting periods beginning after January 1, 2019 are presented under Topic 606 while, as permitted by Topic 606, prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. The Company recorded a cumulative catch up adjustment to beginning accumulated deficit to reflect the impact of adopting Topic 606. The adoption of Topic 606 did not have a material effect on our results of operations for the year ended December 31, 2019. The Company generates revenue from the sale of products and services. Product sales consist of the sale of DABRA and Pharos laser systems, the sale of catheters for use with the DABRA laser, and the sale of consumables and replacement parts. The Company’s sales agreements generally do not include right-of-return provisions for any form of consideration including partial refund or credit against amounts owed to the Company. Services and other revenue primarily consist of sales of extended warranty and billable services, including repair activity and income from rental of lasers. The Company determines revenue recognition incorporating the following steps: • Identification of each contract with a customer; • Identification of the performance obligations in the contract; • Determination of the transaction price; • Allocation of the transaction price to the performance obligations in the contract; and • Recognition of revenue when, or as, performance obligations are satisfied. The Company accounts for a contract with a customer when it has a legally enforceable contract with the customer, the arrangement identifies the rights of the parties, the contract has commercial substance, and the Company determines it is probable that it will collect the contract consideration. The Company recognizes revenue when control of the promised goods or services transfers to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Taxes collected from customers relating to goods or services and remitted to governmental authorities are excluded from revenue. Catheter Revenue The Company enters into a DABRA laser commercial usage agreement or DABRA laser placement acknowledgement with each customer that is supplied a DABRA laser, collectively the “usage agreement”. The usage agreement provides for specific terms of continued use of DABRA laser, including a nominal periodic fee. The terms of a usage agreement typically allow the Company to place a DABRA laser at a customer’s specified location without a specified contract term. Under the usage agreement terms, the Company retains all ownership rights to the DABRA laser and is permitted to request the return of the equipment within 10 business days of notification. While the laser periodic fees are nominal, the laser usage agreements provide the Company the exclusive rights to supply related single-use catheters to the customer which aggregate the majority of the vascular segment revenue. There are no specified minimum purchase commitments for the catheters. The Company recognizes revenue associated with the usage agreement and catheter supply arrangements in accordance with Topic 606 as the contract primarily includes variable payments, the catheters are priced at their standalone selling price and the laser equipment is insignificant in the context of the contract. Revenue is recognized when the performance obligation is satisfied, which is generally upon shipment of the catheter. Laser Sales Sales of laser systems and are included in product sales in the statements of operations. The Company recognizes revenue on laser sales at the point in time that control transfers to the customer. Control of the product typically transfers upon shipment. Warranty Service Revenue The Company typically provides a 12-month warranty with the purchase of its laser systems. Customers can extend the warranty period through the purchase of extended warranty service contracts. Extended warranty service contracts are sold with contract terms ranging from 12 to 60 months and cover periods after the end of the initial 12-month warranty period. The warranty provides the customer with maintenance services in addition to the assurance that the laser product complies with agreed-upon specifications. Therefore, the warranty service is treated as a separate performance obligation from the laser system. Warranty services are a stand-ready obligation, and the Company recognizes revenue on a straight-line basis over the service contract term. Warranty service revenue is included in service and other revenue in the statements of operations. Deferred revenue, on January 1, 2020 and 2019, was $3.3 million and $2.8 million, respectively. Revenue recognized in the years ended December 31, 2020 and 2019 relating to amounts previously included in deferred revenue was $2.0 million and $1.9 million, respectively. The deferred revenue greater than one year will be recognized during the remaining service period through 2024. Distributor Transactions In certain markets outside the U.S., the Company sells products and provides services to customers through distributors that specialize in medical device products. The terms of sales transactions through distributors are generally consistent with the terms of direct sales to customers. The Company accounts for these transactions in accordance with the Company’s revenue recognition policy described herein. Contracts with multiple performance obligations Certain of the Company’s contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if (i) a product or service is separately identifiable from other items in the arrangement and (ii) the customer can benefit from the product or service on its own or with other readily available resources. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling prices based on observable prices of products or services sold separately in comparable circumstances to similar customers. Significant Financing Component For multi-year warranty service contracts in which there is a difference between the cash selling price and the consideration in the contract and a significant amount of time between the payment, which is due up-front, and delivery of the services (greater than one year), the Company records an adjustment for significant financing to reflect the time value of money. The Company recognizes revenue associated with the cash selling price and interest expense using the effective interest method as the Company satisfies its performance obligation(s). The amount of interest expense the Company recognizes over the contract term is based on the contract liability balance, which increases for the accrual of interest and decreases as services are provided. For services contracts that have an original duration of one year or less, the Company uses the practical expedient applicable to such contracts and does not adjust the transaction price for the time value of money. Practical expedients elected As part of the Company’s adoption of Topic 606, the Company elected to use the following practical expedients: • not to adjust the promised amount of consideration for the effects of a significant financing component when the Company expects, at contract inception, that the period between the Company’s transfer of a promised product or service to a customer and when the customer pays for that product or service will be one year or less; • to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less; • to exclude government assessed taxes from the transaction price; and • not to recast revenue for contracts that begin and end in the same fiscal year. Contract Costs The Company capitalizes costs to obtain contracts that are considered incremental and recoverable, such as sales commissions. The capitalized costs are amortized to selling, general and administrative expense over the estimated period of benefit of the asset, which is the contract term. The Company elected to use the practical expedient to expense the costs to obtain a contract when the amortization period is less than one year. The Company has contract costs of $0.2 million and $0.4 million capitalized at December 31, 2020 and December 31, 2019, respectively. Rental Income The Company also adopted ASC Topic 842, Leases The Company also derives income pursuant to product lease agreements for its Pharos laser systems, as operating leases. Consequently, the Company retains title to the equipment and the equipment remains on Company’s balance sheet within property and equipment. Depreciation expense on these leased lasers is recorded to cost of revenues on a straight-line basis. The costs to maintain these leased lasers are charged to cost of revenues as incurred. These lease arrangements contain one lease component (the laser) and one nonlease component (warranty service) for which the Company elected the practical expedient to not separate the nonlease component from the lease component. The Company accounts for the combined lease component as an operating lease and recognizes lease income on a straight-line basis over the lease term. Rental income from lease arrangements for the years ended December 31, 2020 and 2019 was $0.6 million and $0.7 million, respectively.
Shipping and Handling Costs	Shipping and handling costs —Shipping and handling charged to customers is included in net product sales. Shipping and handling costs are included in selling, general and administrative expenses in the accompanying statements of operations. Shipping and handling costs were $0.1 million and $0.5 million for the years ended December 31, 2020 and 2019, respectively
Advertising Expense	Advertising expense —The Company expenses advertising costs as incurred. There was no advertising expense for the year ended December 31, 2020. Advertising expense for the year ended December 31, 2019 was $0.1 million
Research and Development	Research and development —Major components of research and development costs include personnel compensation expenses, stock-based compensation, consulting, materials and clinical trial expenses. Research and development expenses are charged to operations in the period they are incurred.
Patents	Patents —The Company expenses patent costs, including related legal costs, as incurred and records such costs within selling, general and administrative expense in the accompanying statements of operations.
Share-based Compensation	Stock-based compensation — The Company evaluates whether an award should be classified and accounted for as a liability award or equity award for all stock-based compensation awards granted. There were no liability awards outstanding at December 31, 2020 or 2019. Stock-based compensation expense for equity instruments issued to employees and directors is measured based on estimating the fair value of each stock option on the date of grant using the Black Scholes option pricing model. Equity instruments issued to nonemployee consultants and service providers are valued using the Black Scholes option pricing model and are subject to revaluation as the underlying equity instruments vest. The Company recognizes forfeitures as they occur. The Company recognizes stock-based compensation expense as follows: Employees Nonemployees Service condition only Straight-line In the same period and in the same manner as if the Company paid cash for services. Performance criterion is probable of being met: Service criterion is complete Recognize the grant date fair value of the award once the performance criterion is considered probable of occurrence Recognize the grant date fair value of the award once the performance criterion is considered probable of occurrence Service criterion is not complete Straight-line Straight-line unless a performance condition is not probable Performance criterion is not probable of being met No expense is recognized until the performance criterion is considered probable, at which point expense is recognized per above No expense is recognized until the performance criterion is considered probable, at which point expense is recognized per above
Income Taxes	Income taxes —The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences reverse. Any resulting net deferred tax assets are evaluated for recoverability and, accordingly, a valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax asset will not be realized. The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining whether it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. An uncertain tax position is considered effectively settled on completion of an examination by a taxing authority if certain other conditions are satisfied. Should the Company incur interest and penalties relating to tax uncertainties, such amounts would be classified as a component of interest expense and other expense, respectively.
Concentrations of Credit Risk	Concentrations of credit risk —Credit risk represents the accounting loss that would be recognized at the reporting date if counterparties failed completely to perform as contracted. Concentrations of credit risk that arise from financial instruments exist for groups of customers or counterparties when they have similar economic characteristics that would cause their ability to meet contractual obligations to be similarly affected by changes in economic or other conditions described below. Financial instruments, which potentially subject the Company to concentration of credit risk, consist of cash, cash equivalents and short-term investments balances maintained in excess of Federal Depository Insurance Corporation limits, and accounts receivable which have no collateral or security. The Company monitors the financial condition of the banks in which it currently has deposits. The Company has not experienced any significant losses in this respect and believes that it is not exposed to any significant related risk. Exposure to losses on accounts receivable is dependent on the individual customer’s financial condition. The Company monitors its exposure to credit losses and reserves for those accounts receivable that it deems to be not collectible. No individual customer represented greater than 10% of total net revenue for the years ended December 31, 2020 and 2019. One individual customer represented 10% of accounts receivable for each of the years ended December 31, 2020 and 2019, respectively.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements —As an emerging growth company, the Company may elect to adopt new or revised accounting standards when they become effective for non-public companies, which typically is later than public companies must adopt the standards. The Company has elected to take advantage of the extended transition period afforded by the JOBS Act and, as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-public companies, which are the dates included below. In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting . ASU 2018-07 expands the scope of Topic 718, Compensation—Stock Compensation , to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. ASU 2018-07 supersedes Subtopic 505-50, Equity—Equity-Based Payments to Non-Employees . The amendments are effective for fiscal years beginning after December 15, 2019. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The Company adopted this guidance on January 1, 2020 and there was no impact on the financial statements and related disclosures. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), to require the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts and applies to all financial assets, including trade receivables. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. ASU No. 2016-13 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted this guidance on January 1, 2020 and there was no material impact on the financial statements.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of Allowance for Doubtful Accounts Activity	The following table shows the allowance for doubtful accounts activity (in thousands): Year Ended December 31, 2020 2019 Balance at beginning of period $ 355 $ 214 Provision for doubtful accounts 180 283 Deductions (264 ) (142 ) Balance at end of period $ 271 $ 355
Schedule of Property and Equipment Estimated Useful Lives	Property and equipment are recorded at cost and are depreciated on a straight-line basis over their estimated useful lives as follows: Computer hardware and software 4-5 years Furniture and fixtures 5 years Machinery and equipment 5-10 years Lasers 3-5 years Automobiles 5 years

Short-term Investments (Tables)

Short-term Investments (Tables)	12 Months Ended
	Dec. 31, 2020
Short Term Investments [Abstract]
Summary of Debt Securities by Major Security Type	A summary of debt securities by major security type is as follows as of December 31, 2019 (in thousands): Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Debt Securities-available-for-sale: U.S. agency securities $ 1,000 $ — $ — $ 1,000 U.S. government securities 14,967 26 — 14,993 Total debt securities $ 15,967 $ 26 $ — $ 15,993
Summary of Hierarchy for Assets Measured at Fair Value on a Recurring Basis	The following table presents the hierarchy for assets measured at fair value on a recurring basis (in thousands): Total Fair Value Quoted Market Prices for Identical Assets (Level 1) Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) As of December 31, 2020 Money market funds $ 18,394 $ 18,394 $ — $ — As of December 31, 2019 Money market funds $ 13,219 $ 13,219 $ — $ — U.S. government securities $ 14,993 $ 14,993 $ — $ — U.S. agency securities $ 1,000 $ — $ 1,000 $ —

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consisted of the following (in thousands): December 31, 2020 2019 Raw materials $ 1,739 $ 2,300 Work in process 270 215 Finished goods 209 262 Inventories $ 2,218 $ 2,777

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Property Plant And Equipment Net [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following (in thousands): December 31, 2020 2019 Lasers $ 4,677 $ 4,671 Machinery and equipment 866 841 Automobiles 1,054 1,109 Computer hardware and software 353 348 Leasehold improvements 119 119 Furniture and fixtures 48 48 Construction in progress 51 23 Property and equipment, gross 7,168 7,159 Accumulated depreciation (3,957 ) (2,109 ) Property and equipment, net $ 3,211 $ 5,050

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2020
Payables And Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following (in thousands): December 31, 2020 2019 Compensation and related benefits $ 2,602 $ 1,163 Accrued warranty (Note 7) 242 338 Accrued services 1,504 1,141 Accrued expenses $ 4,348 $ 2,642

Accrued Warranty (Tables)

Accrued Warranty (Tables)	12 Months Ended
	Dec. 31, 2020
Product Warranties Disclosures [Abstract]
Schedule Product Warranty Accrual Included in Accrued Expenses	Activity in the product warranty accrual is included in accrued expenses above and consists of the following (in thousands): Year ended December 31, 2020 2019 Balance at beginning of period $ 338 $ 112 Increase in warranty accrual 87 889 Change in liability for pre-existing warranties (2 ) (28 ) Claims satisfied (181 ) (635 ) Accrued warranty $ 242 $ 338

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Schedule of Operating Lease Maturities	The following table presents the lease liabilities within the balance sheet, related to the Company’s operating leases as of December 31, 2020 (in thousands): Years Ending December 31, 2021 $ 528 2022 432 2023 445 2024 459 2025 472 Thereafter 987 Total operating lease payments $ 3,323 Less: imputed interest (703 ) Total operating lease liabilities $ 2,620

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Schedule of Restricted Stock Units Activity	A summary of the activity and related information of the restricted stock units is presented below: Restricted Stock Units Weighted Average Grant Date Fair Value Outstanding at December 31, 2018 59,767 $ 672.75 Granted 12,010 98.75 Vested and released (48,269 ) 698.25 Forfeited (12,644 ) 497.75 Outstanding at December 31, 2019 10,864 $ 128.82 Granted 32,019 10.82 Vested and released (7,906 ) 114.55 Forfeited (1,429 ) 101.79 Outstanding at December 31, 2020 33,548 $ 21.93
Schedule of Restricted Stock Awards Activity	A summary of the activity and related information of the restricted stock awards is presented below: Restricted Stock Awards (in shares) Weighted Average Grant Date Fair Value Outstanding at December 31, 2019 — $ — Granted 286,161 4.77 Forfeited — — Vested — — Outstanding at December 31, 2020 286,161 $ 4.77
Schedule of Stock-based Compensation Expense Recorded in Operating Expenses	Stock-based compensation expense recorded in operating expenses was as follows (in thousands): Year Ended December 31, 2020 2019 Selling, general and administrative $ 3,302 $ 20,392 Research and development 447 1,537 Stock-based compensation in operating expenses $ 3,749 $ 21,929
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Schedule of Options Activity	A summary of the activity and related information of the stock options issued under the 2018 Equity Incentive Plan and the Compensation Plan is presented below: Stock Options Weighted Average Exercise Price Weighted Average Remaining Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2018 76,804 $ 714.75 9.43 $ — Granted 60,854 30.50 Forfeited (12,079 ) 670.25 Outstanding at December 31, 2019 125,579 $ 387.50 9.43 $ — Granted 11,729 30.69 Forfeited (13,137 ) 297.57 Outstanding at December 31, 2020 124,171 $ 363.31 6.42 $ — Exercisable at December 31, 2020 84,376 $ 466.78 5.89 $ — Vested and expected to vest at December 31, 2020 124,171 $ 363.31 6.42 $ —
Stock Options [Member] | 2018 Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Schedule of Fair Value of Options Using the Black Scholes Option Pricing Model and Assumptions Used	The fair value of the stock options issued under the 2018 Plan was estimated using the Black Scholes option pricing model and the weighted-average assumptions used in the model are noted in the following table: Year Ended December 31, 2020 2019 Risk-free interest rate 1.3 % 1.6 % Volatility 58.96 % 59.26 % Expected dividend yield 0.00 % 0.00 % Expected life (in years) 5.8 5.9
Stock Options [Member] | 2020 Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Schedule of Fair Value of Options Using the Black Scholes Option Pricing Model and Assumptions Used	The fair value of the stock options issued under the 2020 Plan was estimated using the Black Scholes option pricing model and the weighted-average assumptions used in the model are noted in the following table: Year Ended December 31, 2020 Risk-free interest rate 0.5 % Volatility 58.33 % Expected dividend yield 0.00 % Expected life (in years) 6.3

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Reconciliation of Differences between United States Statutory Federal Income Tax Rate and Effective Tax Rate	A reconciliation of the differences between the United States statutory federal income tax rate and the effective tax rate as provided in the statements of operations is as follows: Year Ended December 31, 2020 2019 Tax computed at the federal statutory rate 21.0 % 21.0 % State income taxes, net of federal benefits 5.1 1.9 Nondeductible expenses (0.1 ) (0.4 ) Stock-based compensation (2.2 ) (9.5 ) Deferred tax adjustments (57.0 ) — Change in valuation allowance 33.2 (13.0 ) — —
Summary of Federal and State Income Tax Provision	The federal and state income tax provision is summarized as follows (in thousands): Year Ended December 31, 2020 2019 Current Federal $ — $ — State 7 15 7 15 Deferred Federal — — State — — — — Income tax expense $ 7 $ 15
Significant Components of Deferred Tax Assets (Liabilities)	The tax effects of significant components of the Company’s deferred tax assets (liabilities) are as follows (in thousands): December 31, 2020 2019 Deferred Tax Assets: Net operating loss carryforwards $ 3,720 $ 16,096 Operating lease liabilities 691 766 Other accruals 101 61 Accrued compensation 448 — Reserves 299 301 Deferred revenue 642 850 Intangible assets 32 253 Stock-based compensation 4,910 4,821 Total gross deferred tax assets $ 10,843 $ 23,148 Deferred Tax Liabilities: Property and equipment (805 ) (1,026 ) Operating lease right-of-use assets (655 ) (739 ) Other (61 ) (92 ) Total gross deferred tax liabilities $ (1,521 ) $ (1,857 ) Valuation allowance (9,322 ) (21,291 ) Total deferred taxes $ — $ —

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Schedule of Segment Performance	The following tables summarize segment performance (in thousands): Year Ended December 31, 2020 2019 Vascular $ 259 $ 1,275 Dermatology 4,146 5,924 Net revenue $ 4,405 $ 7,199 Vascular $ 1,970 $ 4,036 Dermatology 3,512 4,814 Cost of revenue $ 5,482 $ 8,850 Vascular $ (1,711 ) $ (2,761 ) Dermatology 634 1,110 Gross (loss) profit $ (1,077 ) $ (1,651 )
Schedule of Net Revenue Classified by Major Geographical Areas	Net revenue, classified by the major geographic areas in which our customers are located, was as follows (in thousands): Year Ended December 31, 2020 2019 United States $ 4,181 $ 6,568 All other countries 224 631 Net revenue $ 4,405 $ 7,199

Organization and Nature of Op_2

Organization and Nature of Operations - Additional Information (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Nov. 16, 2020shares	Nov. 15, 2020shares	Jul. 14, 2018$ / sharesshares	Jul. 13, 2018shares
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Common stock, par value | $ / shares	$ 0.0001	$ 0.0001			$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000			25,000,000	10,000,000
Preferred stock, par value | $ / shares	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Stockholders' Equity, Reverse Stock Split	In November 2020, the board of directors approved a Reverse Stock Split ratio of 1-for-25
Stock split ratio	0.04
Common stock, shares issued	3,188,679	550,814	2,900,000	73,000,000
Common stock, shares outstanding	3,188,679	550,814	2,900,000	73,000,000
Accumulated deficit | $	$ 153,202	$ 117,157
Net cash used in operating activities | $	28,304	33,173
Cash and cash equivalents | $	$ 23,906	$ 14,584

Significant Accounting Polici_4

Significant Accounting Policies - Schedule of Allowance for Doubtful Accounts Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Balance at beginning of period	$ 355	$ 214
Provision for doubtful accounts	180	283
Deductions	(264)	(142)
Balance at end of period	$ 271	$ 355

Significant Accounting Polici_5

Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2020
Furniture And Fixtures [Member]
Finite Lived Intangible Assets [Line Items]
Estimated useful lives	5 years
Automobiles [Member]
Finite Lived Intangible Assets [Line Items]
Estimated useful lives	5 years
Minimum [Member] | Computer Hardware And Software [Member]
Finite Lived Intangible Assets [Line Items]
Estimated useful lives	4 years
Minimum [Member] | Machinery And Equipment [Member]
Finite Lived Intangible Assets [Line Items]
Estimated useful lives	5 years
Minimum [Member] | Lasers [Member]
Finite Lived Intangible Assets [Line Items]
Estimated useful lives	3 years
Maximum [Member] | Computer Hardware And Software [Member]
Finite Lived Intangible Assets [Line Items]
Estimated useful lives	5 years
Maximum [Member] | Machinery And Equipment [Member]
Finite Lived Intangible Assets [Line Items]
Estimated useful lives	10 years
Maximum [Member] | Lasers [Member]
Finite Lived Intangible Assets [Line Items]
Estimated useful lives	5 years

Significant Accounting Polici_6

Significant Accounting Policies - Additional Information (Details)	12 Months Ended
	Dec. 31, 2020USD ($)Customer	Dec. 31, 2019USD ($)Customer	Jan. 01, 2020USD ($)	Jan. 01, 2019USD ($)
Deferred revenue			$ 3,300,000	$ 2,800,000
Deferred revenue, recognized	$ 2,000,000	$ 1,900,000
Remaining service period to recognize deferred revenue, description	2024
Capitalized contract cost, net	$ 200,000	400,000
Laser revenue	$ 600,000	$ 700,000
Tax benefit likely of being realized upon ultimate settlement description	measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement.
Customer Concentration Risk | Revenue Benchmark
Concentration risk, percentage	10.00%	10.00%
Number of individual customers representing greater than 10% of bench mark | Customer	0	0
Customer Concentration Risk | Accounts Receivable
Concentration risk, percentage	10.00%	10.00%
Number of individual customers representing greater than 10% of bench mark | Customer	1	1
Shipping and Handling
Shipping and handling costs	$ 100,000	$ 500,000
Advertising expense	$ 0	$ 100,000
Minimum [Member]
Regular warranty service contracts term	12 months
Maximum [Member]
Extended warranty service contracts term	60 months
Capitalized contract cost amortization period	1 year

Short-term Investments - Summar

Short-term Investments - Summary of Debt Securities by Major Security Type (Detail) $ in Thousands	Dec. 31, 2019USD ($)
Schedule Of Available For Sale Securities [Line Items]
Amortized cost	$ 15,967
Gross unrealized gains	26
Fair value	15,993
U.S. Government Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized cost	14,967
Gross unrealized gains	26
Fair value	14,993
U.S. Agency Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized cost	1,000
Fair value	$ 1,000

Short-term Investments - Additi

Short-term Investments - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2019
Maximum [Member]
Marketable Securities [Line Items]
Debt securities maturity period	1 year

Short-term Investments - Summ_2

Short-term Investments - Summary of Hierarchy for Assets Measured at Fair Value on a Recurring Basis (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
U.S. Government Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Fair Value		$ 14,993
U.S. Agency Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Fair Value		1,000
Money market Funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Fair Value	$ 18,394	13,219
Quoted Market Prices for Identical Assets (Level 1) [Member] | U.S. Government Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Fair Value		14,993
Quoted Market Prices for Identical Assets (Level 1) [Member] | Money market Funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Fair Value	$ 18,394	13,219
Other Observable Inputs (Level 2) [Member] | U.S. Agency Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Fair Value		$ 1,000

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 1,739	$ 2,300
Work in process	270	215
Finished goods	209	262
Inventories	$ 2,218	$ 2,777

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 7,168	$ 7,159
Accumulated depreciation	(3,957)	(2,109)
Property and equipment, net	3,211	5,050
Lasers [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	4,677	4,671
Machinery And Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	866	841
Automobiles [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,054	1,109
Computer Hardware And Software [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	353	348
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	119	119
Furniture And Fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	48	48
Construction In Progress [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 51	$ 23

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Abstract]
Depreciation	$ 2	$ 1.4

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Payables And Accruals [Abstract]
Compensation and related benefits	$ 2,602	$ 1,163
Accrued warranty (Note 7)	242	338	$ 112
Accrued services	1,504	1,141
Accrued expenses	$ 4,348	$ 2,642

Accrued Warranty - Schedule Pro

Accrued Warranty - Schedule Product Warranty Accrual Included in Accrued Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Product Warranties Disclosures [Abstract]
Balance at beginning of period, Accrued warranty	$ 338	$ 112
Increase in warranty accrual	87	889
Change in liability for pre-existing warranties	(2)	(28)
Claims satisfied	(181)	(635)
Balance at ending of period, Accrued warranty	$ 242	$ 338

Accrued Warranty - Additional I

Accrued Warranty - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Product Warranty Liability [Line Items]
Warranty expense	$ 100,000	$ 900,000
Accrued warranty (Note 7)	242,000	338,000	$ 112,000
Catheters [Member] | Product Recall [Member]
Product Warranty Liability [Line Items]
Accrued warranty (Note 7)	$ 100,000	$ 200,000

Paycheck Protection Program P_2

Paycheck Protection Program Promissory Note - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	May 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Interest expense		$ 108,000	$ 250,000
PPP Promissory Note [Member] | CARES Act [Member]
Paycheck protection program, amount	$ 2,000,000
Interest rate	1.00%
Payments due, beginning date	Nov. 1, 2020
Payments due, ending date	May 3, 2022
Interest expense		$ 13,000
Deferral period for all loans		10 months
Debt instrument, description		payments are due beginning August 2021 and the principal amount along with unpaid interest is due in May 2022. The Company has requested from its lender an extension of the loan maturity from two years to five years as permitted under the PPPFA. The principal and interest may be forgiven if the proceeds are used for forgivable purposes as defined by the terms in the PPP Promissory Note, and the Company believes it has used the proceeds from the PPP Promissory Note for forgivable purposes as defined by the terms of the PPP Promissory Note.
PPP Promissory Note [Member] | CARES Act [Member] | Minimum [Member]
Extended maturity period		2 years
PPP Promissory Note [Member] | CARES Act [Member] | Maximum [Member]
Extended maturity period		5 years

Leases - Additional Information

Leases - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)Lease	Dec. 31, 2019USD ($)	Jan. 01, 2019USD ($)
Operating Leased Assets [Line Items]
Operating lease right-of-use-assets	$ 2,484	$ 2,835
Operating lease, liability	$ 2,620
Number of leases | Lease	2
Operating lease, discount rate	7.00%
Operating lease, weighted average remaining lease term	7 years
Operating lease expense	$ 500	500
Operating lease , cash payment	500	500
Operating lease right-of-use-assets amortization	$ 400	$ 300
Office Building [Member]
Operating Leased Assets [Line Items]
Lease expiration period	2027
Manufacturing Facility [Member]
Operating Leased Assets [Line Items]
Lease expiration period	2021
ASU 2016-02 [Member]
Operating Leased Assets [Line Items]
Operating lease right-of-use-assets			$ 3,200
Operating lease, liability			$ 3,200

Leases - Lease Liabilities Rela

Leases - Lease Liabilities Related to Operating Leases Presented within Condensed Balance Sheet (Details) $ in Thousands	Dec. 31, 2020USD ($)
Leases [Abstract]
2021	$ 528
2022	432
2023	445
2024	459
2025	472
Thereafter	987
Total operating lease payments	3,323
Less: imputed interest	(703)
Total operating lease liabilities	$ 2,620

Equipment Financing - Additiona

Equipment Financing - Additional Information (Details) - Automobile Loan [Member]	12 Months Ended
	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018agreementAutomobile
Debt Instrument [Line Items]
Number of loan agreements | agreement			4
Interest expense	$ 28,000	$ 48,000
Number of automobiles financed | Automobile			25
Weighted average interest rate	6.50%
Debt instruments outstanding balance	$ 300,000
Debt instruments maturity year	2021
Debt instruments maturity date	Mar. 31, 2021

Loss per Share - Additional Inf

Loss per Share - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Loss allocated to participating securities	$ 0
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents excluded from computation of diluted net loss per share	142,171	125,579
Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents excluded from computation of diluted net loss per share	2,345,033
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents excluded from computation of diluted net loss per share	33,548	10,864
Employee Stock Purchase Plan [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents excluded from computation of diluted net loss per share	3,200	2,473
Restricted Stock Awards (RSAs) [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents excluded from computation of diluted net loss per share	290,536

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended
	Aug. 31, 2020	Jun. 30, 2020	May 31, 2020	Dec. 31, 2020	May 22, 2020	Dec. 31, 2019	Jul. 14, 2018	Jul. 13, 2018
Class Of Stock [Line Items]
Common stock, shares authorized				300,000,000		300,000,000	25,000,000	10,000,000
Common stock, par value				$ 0.0001		$ 0.0001	$ 0.0001
Stock issued during period shares warrants Exercised		73,506
Preferred stock, shares outstanding				0		0
May 2020 Offering [Member]
Class Of Stock [Line Items]
Common stock, shares authorized			888,888
Warrants issued price per share					$ 11.25
Proceeds from issuance of common stock			$ 8.7
Other offering expenses			1.3
Valuation of warrants			$ 3.5
Volatility rate			59.86%
Risk-free interest rate			0.34%
Expected dividend yield			0.00%
Expected terms (In Years)			2 years 6 months
Common stocvk reserve for issuance				815,382
May 2020 Offering [Member] | Warrant [Member]
Class Of Stock [Line Items]
Common stock, par value			$ 11.25
Equity offering description			Each share of common stock was sold in the offering with one warrant to purchase one share of common stock
Warrants issued price per share			$ 11.25
Warrants expire period			5 years
May 2020 Offering [Member] | Maximum [Member] | Warrant [Member]
Class Of Stock [Line Items]
Warrants issued during period			888,888
May 2020 Offering [Member] | Placement Agent Warrants [Member]
Class Of Stock [Line Items]
Common stocvk reserve for issuance				62,222
May 2020 Offering [Member] | Placement Agent Warrants [Member] | Warrant [Member]
Class Of Stock [Line Items]
Warrants issued price per share			$ 14.0625
Common stock expire period			5 years
May 2020 Offering [Member] | Placement Agent Warrants [Member] | Maximum [Member] | Warrant [Member]
Class Of Stock [Line Items]
Placement agent warrants issued			62,222
May 2020 Offering [Member] | Offering [Member]
Class Of Stock [Line Items]
Warrants issued price per share					$ 14.0625
August 2020 Offering [Member]
Class Of Stock [Line Items]
Common stock, shares authorized	1,371,429
Warrants issued price per share	$ 8.75
Proceeds from issuance of common stock	$ 10.4
Other offering expenses	1.6
Valuation of warrants	$ 4
Volatility rate	59.72%
Risk-free interest rate	0.17%
Expected dividend yield	0.00%
Expected terms (In Years)	2 years 6 months
Common stocvk reserve for issuance				1,371,429
August 2020 Offering [Member] | Warrant [Member]
Class Of Stock [Line Items]
Common stock, par value	$ 8.75
Equity offering description	Each share of common stock was sold in the offering with one warrant to purchase one share of common stock
Warrants issued price per share	$ 8.75
Warrants expire period	5 years
August 2020 Offering [Member] | Maximum [Member] | Warrant [Member]
Class Of Stock [Line Items]
Warrants issued during period	1,371,429
August 2020 Offering [Member] | Placement Agent Warrants [Member]
Class Of Stock [Line Items]
Common stocvk reserve for issuance				96,000
August 2020 Offering [Member] | Placement Agent Warrants [Member] | Warrant [Member]
Class Of Stock [Line Items]
Warrants issued price per share	$ 10.9375
Common stock expire period	5 years
August 2020 Offering [Member] | Placement Agent Warrants [Member] | Maximum [Member] | Warrant [Member]
Class Of Stock [Line Items]
Placement agent warrants issued	96,000
August 2020 Offering [Member] | Offering [Member]
Class Of Stock [Line Items]
Warrants issued price per share	$ 10.9375

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 04, 2018	Sep. 30, 2018	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Mar. 13, 2020	Jun. 08, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation			$ 4,082	$ 23,543
Weighted Average Remaining Life (in years)			1 year 2 months 12 days
2018 Stock Compensation Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stocvk reserve for issuance	132,000	132,000	65,285
Maximum annual increase of outstanding stock reserved for future issuance, Percentage			5.00%
Number of shares available for grant under the plan			110,329
2020 Inducement Equity Incentive Plan (the "2020 plan") [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stocvk reserve for issuance						32,000
Number of shares granted under the plan			18,000
Weighted average exercise price of stock options			$ 25.50
Number of shares exercisable under the plan			3,375
2018 Employee Stock Purchase Plan (ESPP) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stocvk reserve for issuance			11,870
Maximum annual increase of outstanding stock reserved for future issuance, Percentage			1.25%
Number of shares available for grant under the plan			19,463
Common stock discount rate			85.00%
Shares issued under employee stock purchase plan, Shares			5,278	368
Shares issued under employee stock purchase plan, Value			$ 42,000	$ 37,000
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares granted under the plan			11,729	60,854
Weighted average exercise price of stock options			$ 30.69	$ 30.50
Number of shares exercisable under the plan			84,376
Stock-based compensation			$ 300	$ 1,600
Unrecognized compensation expense for stock options issued			$ 1,800
Weighted Average Remaining Life (in years)			6 years 5 months 1 day	9 years 5 months 4 days	9 years 5 months 4 days
Stock Options [Member] | 2018 Stock Compensation Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Authorized replacement equity awards of stock options and restricted stock units	76,076
Share-based compensation arrangement by share-based payment award, Award vesting rights	generally vest 33% on the first anniversary of the grant date with the balance vesting monthly over the remaining two years
Share based compensation awards expiration date		Jan. 31, 2020
Stock Options [Member] | 2018 Stock Compensation Plan [Member] | First Anniversary [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted under the 2018 Plan vesting percentage	33.00%	25.00%
Stock Options [Member] | 2018 Stock Compensation Plan [Member] | Second Anniversary [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted under the 2018 Plan vesting percentage		25.00%
Stock Options [Member] | 2018 Stock Compensation Plan [Member] | Third Anniversary [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted under the 2018 Plan vesting percentage		25.00%
Stock Options [Member] | 2018 Stock Compensation Plan [Member] | Forth Anniversary [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted under the 2018 Plan vesting percentage		25.00%
Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense for stock options issued			$ 600
Weighted-average recognized period			1 year 10 months 24 days
Restricted Stock Units (RSUs) [Member] | 2018 Stock Compensation Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Authorized replacement equity awards of stock options and restricted stock units							53,633
Restricted Stock Awards (RSAs) [Member] | 2020 Inducement Equity Incentive Plan (the "2020 plan") [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock awards granted			5,000
Restricted stock awards with grant date fair value			$ 100
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense for stock options issued			$ 1,400
Weighted-average recognized period			2 years 9 months 18 days

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Options Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Weighted Average Remaining Life (in years)
Weighted Average Remaining Life (in years)	1 year 2 months 12 days
Stock Options [Member]
Options outstanding
Beginning balance	125,579	76,804
Number of shares granted under the plan	11,729	60,854
Forfeited	(13,137)	(12,079)
Ending balance	124,171	125,579	76,804
Number of shares exercisable under the plan	84,376
Vested and expected to vest at the end of the period	124,171
Weighted Average Exercise Price
Beginning balance	$ 387.50	$ 714.75
Weighted average exercise price of stock options	30.69	30.50
Forfeited	297.57	670.25
Ending balance	363.31	$ 387.50	$ 714.75
Exercisable at the end of the period	466.78
Vested and expected to vest at the end of the period	$ 363.31
Weighted Average Remaining Life (in years)
Weighted Average Remaining Life (in years)	6 years 5 months 1 day	9 years 5 months 4 days	9 years 5 months 4 days
Exercisable at the end of the period	5 years 10 months 20 days
Vested and expected to vest at the end of the period	6 years 5 months 1 day

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Restricted Stock Units
Beginning balance	10,864	59,767
Granted	32,019	12,010
Vested and released	(7,906)	(48,269)
Forfeited	(1,429)	(12,644)
Ending balance	33,548	10,864
Weighted Average Grant Date Fair Value
Beginning balance	$ 128.82	$ 672.75
Granted	10.82	98.75
Vested and released	114.55	698.25
Forfeited	101.79	497.75
Ending balance	$ 21.93	$ 128.82

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Restricted Stock Awards Activity (Details) - Restricted Stock	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted | shares	286,161
Ending balance | shares	286,161
Granted | $ / shares	$ 4.77
Ending balance | $ / shares	$ 4.77

Stock-Based Compensation - Sc_4

Stock-Based Compensation - Schedule of Stock-based Compensation Expense Recorded in Operating Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation in operating expenses	$ 3,749	$ 21,929
Selling, General and Administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation in operating expenses	3,302	20,392
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation in operating expenses	$ 447	$ 1,537

Stock-Based Compensation - Sc_5

Stock-Based Compensation - Schedule of Fair Value of Options Using the Black Scholes Option Pricing Model and Weighted Average Assumptions Used (Details) - Stock Options [Member]	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
2018 Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	1.30%	1.60%
Volatility	58.96%	59.26%
Expected dividend yield	0.00%	0.00%
Expected life (in years)	5 years 9 months 18 days	5 years 10 months 24 days
2020 Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	0.50%
Volatility	58.33%
Expected dividend yield	0.00%
Expected life (in years)	6 years 3 months 18 days

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Differences between United States Statutory Federal Income Tax Rate and Effective Tax Rate (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Tax computed at the federal statutory rate	21.00%	21.00%
State income taxes, net of federal benefits	5.10%	1.90%
Nondeductible expenses	(0.10%)	(0.40%)
Stock-based compensation	(2.20%)	(9.50%)
Deferred tax adjustments	(57.00%)
Change in valuation allowance	33.20%	(13.00%)

Income Taxes - Summary of Feder

Income Taxes - Summary of Federal and State Income Tax Provision (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Current
State	$ 7	$ 15
Current federal and state income tax expense	7	15
Deferred
Income tax expense	$ 7	$ 15

Income Taxes - Significant Comp

Income Taxes - Significant Components of Deferred Tax Assets (Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred Tax Assets:
Net operating loss carryforwards	$ 3,720	$ 16,096
Operating lease liabilities	691	766
Other accruals	101	61
Accrued compensation	448
Reserves	299	301
Deferred revenue	642	850
Intangible assets	32	253
Stock-based compensation	4,910	4,821
Total gross deferred tax assets	10,843	23,148
Deferred Tax Liabilities:
Property and equipment	(805)	(1,026)
Operating lease right-of-use assets	(655)	(739)
Other	(61)	(92)
Total gross deferred tax liabilities	(1,521)	(1,857)
Valuation allowance	$ (9,322)	$ (21,291)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details)	12 Months Ended
	Dec. 31, 2020USD ($)
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards expiration year	2032
Deferred tax expense impact	$ 20,800,000
Unrecognized tax benefits	0
Anticipated amount of unrecognized tax benefits significantly increase or decrease in next 12 months	0
Unrecognized tax benefits accrued interest and penalties	$ 0
Income tax examination years under examination	2016 and later
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 14,300,000
State [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 13,400,000

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Jan. 19, 2021	Dec. 28, 2020	Jan. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Other Commitments [Line Items]
Audit committee findings				The primary investigative findings were: (i) the DABRA catheter frequently failed to calibrate and occasionally overheated, posing a risk of injury to physicians and patients; (ii) the Company’s explanations regarding its fourth quarter 2018 and first quarter 2019 sales created a risk of confusion because they did not explicitly reference inconsistent DABRA catheter performance and catheter failures; (iii) the Company failed to timely make at least two Medical Device Reports, or MDRs, to the FDA; (iv) the Company, out of a concern for the DABRA catheters’ performance, engaged in systematic efforts to replace product held by customers, which constituted product recalls, but were not documented as such, (v) the Company lack documentation of sufficient detail and specificity to support certain payments to physicians, ostensibly for training and consulting services, and as to three physicians did not accurately reflect the purpose and nature of approximately $300,000 of payments, which could be perceived as an improper attempt to obtain business or to gain special advantage, (vi) while the indication for use in the 510(k) clearance the Company obtained for the DABRA system is not for atherectomy, the Company’s salespeople were instructed to characterize DABRA as performing atherectomy and to encourage doctors to seek reimbursement using atherectomy codes, (vii) the Company’s determinations to direct potentially valuable benefits and opportunities to doctors were informed in part by sales prospects, and (viii) the Company received complaints regarding regulatory or compliance concerns that, because they implicated executive officers, should have been brought to the attention of the Board or the Audit Committee, but were not.
Payments to physicians that lack documentation of sufficient detail				$ 300,000
Revenue				4,405,000	$ 7,199,000
Loss contingency, payments		$ 2,700,000
Settlement accrued expenses				$ 300,000
Retirement benefits, description				In January 2019, the Company established a defined contribution plan under Section 401(k) of the Internal Revenue Code (“401(k) Plan”) that the Company administers for participating employees’ contributions.
Defined contribution plan, description				All full-time employees are eligible under the 401(k) Plan. The Company will make contributions, based on a match of 100% of each employee’s contribution up to 3% and 50% of contributions between 3% and 5%, with the match-eligible contribution being limited to 4% of the employee’s eligible compensation.
Defined benefit contribution plan expense				$ 300,000	$ 300,000
First Anniversary [Member]
Other Commitments [Line Items]
Employer matching contribution, maximum (percentage)			100.00%
Maximum contribution per employee (percentage)			3.00%
Second Anniversary [Member]
Other Commitments [Line Items]
Employer matching contribution, maximum (percentage)			50.00%
Third Anniversary [Member]
Other Commitments [Line Items]
Maximum contribution per employee (percentage)			4.00%
Subsequent Event [Member]
Other Commitments [Line Items]
Litigation settlement agreement, amount paid	$ 265,000
Maximum [Member] | Second Anniversary [Member]
Other Commitments [Line Items]
Maximum contribution per employee (percentage)			5.00%
Minimum [Member] | Second Anniversary [Member]
Other Commitments [Line Items]
Maximum contribution per employee (percentage)			3.00%
Settlement Agreement [Member]
Other Commitments [Line Items]
Allegations description				(a) paid illegal remuneration to certain physicians to induce them to use the DABRA laser system in violation of the federal anti-kickback statute and (b) marketed the DABRA laser system for off-label use in atherectomy procedures despite product performance issues causing calibration and overheating problems, which posed a risk to physicians and patients (the “Covered Conduct”).
Litigation settlement amount, current				$ 2,400,000
Litigation settlement, remaining amount				100,000
Settlement amount , year 2021		$ 500,000
Settlement year one		2021
Settlement amount , year 2022		$ 750,000
Settlement year two		2022
Settlement amount , year 2023		$ 1,000,000
Settlement year three		2023
Settlement amount , year 2024		$ 1,250,000
Settlement year four		2024
Business acquisition, settlement amount		$ 5,000,000
Business acquisition additional settlement percentage		4.00%
Settlement claim		$ 56,000,000
Settlement expense		200,000
Settlement Agreement [Member] | Maximum [Member]
Other Commitments [Line Items]
Litigation settlement amount				$ 2,500,000
Revenue		10,000,000
Business acquisition change In control payments		28,000,000
Settlement Agreement [Member] | Minimum [Member]
Other Commitments [Line Items]
Business acquisition, transaction costs		$ 100,000,000
Integrity Agreement [Member]
Other Commitments [Line Items]
Agreement term				5 years

Segment Information - Additiona

Segment Information - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)Segment	Dec. 31, 2019USD ($)
Segment Reporting Information [Line Items]
Number of operating segments | Segment	2
Property and equipment, net	$ 3,211	$ 5,050
Vascular [Member]
Segment Reporting Information [Line Items]
Property and equipment, net	1,900	2,600
Dermatology [Member]
Segment Reporting Information [Line Items]
Property and equipment, net	$ 700	$ 900

Segment Information - Summary o

Segment Information - Summary of Segment Performance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Net revenue	$ 4,405	$ 7,199
Cost of revenue	5,482	8,850
Gross loss	(1,077)	(1,651)
Vascular [Member]
Segment Reporting Information [Line Items]
Net revenue	259	1,275
Cost of revenue	1,970	4,036
Gross loss	(1,711)	(2,761)
Dermatology [Member]
Segment Reporting Information [Line Items]
Net revenue	4,146	5,924
Cost of revenue	3,512	4,814
Gross loss	$ 634	$ 1,110

Segment Information - Summary_2

Segment Information - Summary of Net Revenue Classified by Major Geographic Areas (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	$ 4,405	$ 7,199
United States [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	4,181	6,568
All other countries [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenue	$ 224	$ 631